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Patients who undergo cardiac surgery are at high risk of delirium (incidence: 50-90%), increasing the risk of 
death and adversely affecting recovery. Clinical interventional trials have been conducted to prevent and treat 
postoperative delirium pharmacologically including antipsychotics and sedatives. These trials have provided 
some evidence about efficacy and influenced clinical decision making. However, much reporting is incomplete 
and provides biased assessments of efficacy; benefits are emphasised while harms are inadequately 
reported. The purpose of this study was to undertake a systematic review using the Joanna Briggs Institute 
(JBI) methodology that aimed at identifying and synthesising the best available evidence about the 
effectiveness and harms of pharmacological interventions in the treatment of delirium in adult intensive care 
patients after cardiac surgery.    
Inclusion Criteria 
Types of participants 
Participants were ≥ 16 years, any gender or ethnicity, who were treated postoperatively in a cardiothoracic 
intensive care unit (ICU) following cardiac surgery and identified as having delirium. 
Types of interventions  
Any pharmacological intervention for the treatment of delirium was included, regardless of drug classification, 
dosage or frequency of administration. 
Types of comparators 
Studies that compared any pharmacological interventions for the treatment of delirium in patients who were 
admitted in the ICU after cardiac surgery.  No limitations were placed on drug classification, dosage of the 
medications or frequency of administration. 
Types of outcomes 
This systematic review examined eleven primary and five secondary outcomes of interest. The primary 
outcomes of interest included: mortality, duration and severity of delirium, use of physical restraints, quality 
of life, family members satisfaction with delirium management, duration/severity of the aggressive episode, 
associated falls, severity of accidental self-harm, pharmacological harms, and harms related to over-sedation.  
Types of studies 
Randomised controlled trials (RCTs) were considered first and in their absence, non-RCTs and quasi-




A comprehensive search was conducted across seven databases, three clinical trial registers and a database 
for dissertations and theses as well as a hand search for published primary studies.  
Methodological quality 
Two reviewers assessed the methodological quality of the included studies using standardised critical 
appraisal instruments from JBI and McMaster University.  
Data extraction 
Quantitative data were extracted using the standardised JBI data extraction tool. A meta-analysis was not 
performed as there was too much clinical and methodological heterogeneity in the included studies. Results 
have been presented in a narrative form. Standard GRADE (Grading of Recommendations, Assessment, 
Development, and Evaluation) evidence assessment of outcomes has been reported. 
Results 
Three RCTs investigating morphine vs haloperidol (n=53), ondansetron vs haloperidol (n=72) and 
dexmedetomidine vs midazolam (n=80) were included. Overall the methodological quality of these studies 
was found to be low. There is currently insufficient evidence to confirm or refute the effectiveness of morphine 
compared with haloperidol, ondansetron compared with haloperidol or dexmedetomidine compared with 
midazolam for reducing the duration or severity of hyperactive delirium in the postoperative cardiac surgical 
patient treated in the ICU. Additionally, this review found reporting of harms to be inadequate for all three 
studies and did not meet the required standards for harms reporting. 
Conclusions 
This review was unable to draw any valid conclusions regarding the effectiveness of the included 
pharmacological interventions in treating delirium after cardiac surgery. This is due to the low number of 
studies, the poor methodological quality in conducting and reporting and the heterogeneity between the 
studies. 
Implications for practice 
There is insufficient evidence to support the use of morphine, ondansetron or dexmedetomidine as effective 
pharmacological agents in treating delirium. It is imperative that clinicians remain vigilant to the known 
indications, contraindications and harms of the pharmacological agents that are being administered and to 
understand the implications of such drugs on cardiac performance in the initial postoperative recovery phase 









DECLARATION OF ORIGINALITY OF WORK 
_____________________________________________________________________________________ 
 
I certify that this work contains no material which has been accepted for the award of any other degree or 
diploma in my name, in any university or other tertiary institution and, to the best of my knowledge and belief, 
contains no material previously published or written by another person, except where due reference has been 
made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my 
name, for any other degree or diploma in any university or other tertiary institution without the prior approval 
of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of 
this degree.  
I acknowledge that copyright of published works contained within this thesis resides with the copyright 
holder(s) of those works.  
I also give permission for the digital version of my thesis to be made available on the web, via the University’s 
digital research repository, the Library Search and also through web search engines, unless permission has 
been granted by the University to restrict access for a period of time.  
I acknowledge the support I have received for my research through the provision of an Australian Government 
Research Training Program Scholarship.  
 
     
____________________________________________________ 








I would like to take this opportunity to thank my past and present supervisors Dr. Cindy Stern, Dr. Rosalind 







LIST OF TABLES 
 
Table 1: Application of GRADE quality of evidence in the GRADE approach ............................................... 16 
Table 2: GRADE ratings and their interpretation ........................................................................................... 17 
Table 3: Critical appraisal results of eligible studies using the JBI Critical Appraisal Checklist for 
Randomised Controlled Trials ....................................................................................................................... 27 
Table 4: Critical appraisal results of eligible studies using the McMaster quality assessment scale of harms 
(McHarms) critical analysis ........................................................................................................................... 29 
Table 5: Characteristics of participants in the included studies ..................................................................... 31 
Table 6: Characteristics of the interventions in the included studies ............................................................. 32 
Table 7: Summary of the measured primary outcomes of the included studies ............................................ 33 
Table 8: Summary of the measured secondary outcomes of the included studies ....................................... 34 
Table 9: Summary of the reporting of harms using McHarm appraisal tool of the included studies .............. 37 
Table 10: Morphine vs Haloperidol ............................................................................................................... 47 
Table 11: Ondansetron vs Haloperidol ......................................................................................................... 48 




LIST OF FIGURES 
 
Figure 1: The JBI Model................................................................................................................................ 12 





CHAPTER 1: INTRODUCTION  
_____________________________________________________________________________________ 
The focus of this thesis is the presentation of a systematic review following the Joanna Briggs Institute (JBI) 
methodology for reviewing evidence on the effectiveness of an intervention. The review question sought to 
identify and synthesise the best available evidence on the effectiveness and harms of pharmacological 
interventions for the treatment of hyperactive delirium following cardiac surgery in patients treated in the 
intensive care unit (ICU). The aim was to explore the effect on the following key outcomes; mortality, duration 
and severity of delirium, the use of physical restraints, quality of life, family members satisfaction with delirium 
management, duration/severity of the aggressive episode, associated falls, severity of accidental self-harm, 
pharmacological harms, harms related to over-sedation, ICU length of stay, hospital length of stay (after the 
ICU stay), total hospital length of stay, need for additional intervention medication and need for rescue 
medication. 
 
1.1 Thesis structure  
This thesis is organised into the following five chapters: 
Chapter 1: Introduction:  
In the first chapter a background to the topic of interest is provided - delirium following cardiac surgery in 
adults admitted into the ICU. The chapter will define delirium and explain the various subtypes of delirium. 
The incidence rates and associated risk factors will also be discussed before outlining the pathophysiology 
behind the manifestation of delirium and the recommended strategies for identifying and screening. This will 
then be followed with a discussion on current management and treatment strategies. Finally, an overview of 
the current research is also provided, along with a rationale for undertaking a systematic review on this topic.  
 
Chapter 2: Methodology: 
In chapter two, the methodological principles upon which the systematic review of international literature is 
based are addressed. This includes a description of the development and origins of evidence-based 





Chapter 3: Systematic review methods:  
In the third chapter the methodological process undertaken in the systematic review underpinning this thesis 
is described. Outlined in this chapter are the review objective/question, inclusion criteria including types of, 
participants, interventions, comparators, the primary and secondary outcomes and types of studies. The 
search and selection process are detailed alongside the appraisal process for methodological quality, the 
process utilised for data extraction and the method of data synthesis. 
 
Chapter 4: Results:  
The search results and the methodological quality and characteristics of the included studies are described 
in Chapter four. The findings of the review are also presented in this chapter. 
 
Chapter 5: Discussion, conclusions and recommendations for practice and research: 
In the final chapter the main findings generated from the systematic review, the limitations of the review and 
the implications for practice and research are discussed. 
 
1.2 Overview of chapter 1 
The remaining part of chapter one of this thesis is broken down into the following sections: an overview of 
delirium with reference to definition (section 1.3), delirium subtypes (section 1.4), national and international 
incidence rates (section 1.5), the associated risk factors for delirium (section 1.6), pathophysiology (section 
1.7), recognition and screening (section 1.8), management and treatment with reference to non-
pharmacological and pharmacological management (section 1.9), overview of current literature  (section 1.10) 
and relationship between existing literature and rationale for conducting a systematic review on this topic 
(section 1.11). 
1.3 Contextual overview of delirium 
Delirium after cardiac surgery is a common phenomenon that may have unwanted short and long-term 
implications.1-4 According to the Diagnostic and Statistical Manual of Mental Disorders (DSM) V, delirium is 
defined as an acute alteration in cognition which is characterised by fluctuating mental alertness, confusion 
and behavioural disturbances.4, 5   
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1.4 Delirium subtypes 
Delirium is classified into three motoric subtypes; hyperactive (characterized by agitation, increased 
psychomotor activity, hallucinations and restlessness), hypoactive (characterized by reduced level of 
consciousness, withdrawal and inattention) and mixed (characterised by fluctuations between hyper and 
hypoactive subtypes) which affect sleep, psychomotor activities and emotions to differing degrees.6-9 Due to 
the restless and agitated nature of the symptoms, hyperactive delirium is easier to identify yet, it is associated 
with an increased risk of harm and injury to self and others.3 However, hypoactive delirium has been shown 
to be associated with worse outcomes compared to hyperactive and mixed delirium largely as a result of 
under-recognition.7, 8 Although reversible, delirium is a precursor to poor patient outcome following the 
delirium episode and this often initiates a cascade of events.2, 10, 11 For the patient, cognitive impairment 
following the delirium episode is known to affect attention and reasoning, memory and processing speed that 
can manifest as relatively minor to severe cognitive impairment.12 Prolonged delirium can result in worse 
outcomes for up to one year following the episode;  35% of patients experiencing it die within six months of 
hospital discharge.12-16 The impact on the individuals’ long-term health, their families, health services and the 
wider community is of significant public health importance.17 For the healthcare system, increased costs are 
incurred with prolonged length of stay, requiring additional staffing, medication, safety equipment and 
rehabilitation.2, 9, 12, 13, 18, 19 Internationally, the annual cost has been estimated at 1200€ (1909.32AUD) per 
diagnosed delirium patient while the cost to the Australian healthcare system has been found to be two and 
a half times greater than for non-delirious patients.2, 20 
1.5 Incidence 
Delirium occurs at any age and in any setting. Patients admitted for treatment in ICU are at greatest risk.21 In 
Australia, the incidence of delirium in ICU has been reported at 37% (using unstandardised assessment 
methods) and 21% (using standardised assessment methods).22 In a multicentre Australian and New Zealand 
study, the incidence was determined to be 45% (standardised assessment) and international studies report 
delirium to affect 3-90% of hospitalised patients.22-24 The discrepancy and variation in incidence is dependent 
upon the methodology used to screen and assess for delirium, the characteristics of the patients (e.g. age, 
severity of illness) and the competence of those identifying and screening for delirium. 
1.6 Associated risk factors 
The risk factors associated with delirium are classified according to whether they predispose or precipitate 
delirium.24 In cardiac surgical patients, delirium is associated with specific preoperative, intraoperative and 
postoperative factors.11, 25 There is strong evidence that preoperative predisposing risk factors may include 
advanced age, hypertension, decreased ejection fraction, atrial fibrillation, pulmonary hypertension, diabetes, 
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body mass index (BMI), impaired renal perfusion, vascular disease, cerebrovascular disease, pre-existing 
cognitive impairment, preoperative cognitive impairment, emergency surgery, drug and alcohol use. 11, 17, 24, 
26 Intraoperatively, open heart surgery is typically performed either with (on-pump) or without (off-pump) the 
use of cardiopulmonary bypass (CPB).11, 27-29 Incorporating CPB (on-pump) allows cardiac surgery to be 
performed with a bloodless field.27,28 Cardiopulmonary bypass involves the insertion of an extracorporeal 
circuit that provides circulatory and respiratory function to facilitate surgery on the heart and coronary 
vessels.27,28 Utilising CPB may be accompanied with significant hypothermia, hypoxia or hypoxemia, that is 
usually associated with a systemic inflammatory response and haemodynamic instability.11 This is potentially 
due to the induced hypothermic state required for use of CPB, thus leading to patients requiring extended 
anaesthetic time and blood transfusions.11 Studies have revealed a strong association between delirium and 
on-pump cardiac surgeries compared with off-pump surgeries.27, 29 The postoperative risk factors that may 
precipitate delirium include prolonged mechanical ventilation associated with continuous infusions of sedative 
medications, opioids for pain management, atrial fibrillation, hypotension, sleep disruption, cardiogenic shock 
and sepsis.11 These predisposing and precipitating risk factors may be further exaggerated by the 
environmental impact of intensive care due to sleep deprivation, windowless rooms, noise, light disturbances 
and multiple occupancy rooms.30 These factors have been found to disrupt patient sleep-wake cycles 
(circadian rhythms) placing them at greater risk of delirium.31, 32  
1.7 Pathophysiology 
While the exact neurophysiological mechanism and causation of delirium remains unclear, there are 
published studies that have provided some explanation of the underlying mechanism.33-35 In 1998, an 
exploration of the pathophysiology of delirium was published by van der Mast,35 providing an explanation for 
the underlying mechanism of delirium as being underpinned by the neurotransmitter hypothesis and the 
inflammatory hypothesis.35 The potential cerebral dysfunction was proposed to be a result of dysregulation in 
cholinergic, monaminergic, cerebral y-aminobutyric acid, glutamate and histamine neurotransmitters.35 
Gunther, 2008 33 developed this area further by exploring neurotransmitter dysfunction using neuroimaging, 
suggesting that delirious patients experienced a 42% reduction in cerebral blood flow in the subcortical and 
occipital regions that leads to widespread brain dysfunction.33 
A more recent explanation of the underlying mechanism of delirium was published by Maldonado in 2013.34 
Maldonado explored several hypotheses; the neuroinflammatory hypothesis (NIH), the neuronal aging 
hypothesis (NAH), the oxidative stress hypothesis (OSH), the neurotransmitter hypothesis (NTH), the 
neuroendocrine hypothesis (NEH), the diurnal dysregulation or melatonin dysregulation hypothesis, and 
finally, the network dysconnectivity hypothesis (NDH).34  
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The NIH proposes an acute over-stimulation of inflammatory markers as a result of surgery, infection or 
trauma that leads to delirium symptoms.34 It has been suggested that surgical procedures involving extensive 
tissue damage, use of anesthetic agents, blood loss requiring blood transfusions, the use of extracorporeal 
circulation (bypass), hypoxia, ischemia and re-profusion may trigger inflammatory markers activating the 
inflammatory cascade that overwhelms the system leading to delirium.34 The NAH suggests that aging leads 
to cerebral changes in stress-regulating neurotransmitters, reduced blood flow and vascular density and a 
loss of neuron and intracellular signal transduction leading to the elderly becoming increasingly vulnerable to 
stress and illness.34 The OSH suggests that hypoperfusion induces chronic oxidative stress as a result of 
tissue damage, hypoxia, severe illness and infection that overwhelms oxygen and glucose availability with 
metabolic demand, which may lead to cerebral dysfunction.34 The NTH proposes that delirium occurs as a 
result of substances (e.g. medications, toxins) that alter neurotransmitter function and availability, leading to 
imbalances in neurotransmitter function,34 while the NEH proposes that delirium occurs as a result of acute 
stress that is mediated by abnormally high glucocorticoid steroid levels.34 Glucocorticoid steroid hormones 
impair cerebral neurons resulting in the reduced ability of neurons to survive after various metabolic insults.34 
The diurnal dysregulation or melatonin dysregulation hypothesis suggests that disruptions to the 24-hour 
circadian cycle may lead to disturbances in sleep patterns leading to melatonin imbalances and sleep 
deprivation as a result of circadian rhythm disruption.34 Current evidence suggests that the acute and chronic 
impact of sleep deprivation is associated with altered endocrine and metabolic functions, cortisol release 
contributing to glucocorticoid steroid hormone imbalance, glucose tolerance, insulin resistance and 
inflammatory processes.32, 34 Finally, the NDH proposes that various factors, such as toxins, disease, 
inflammation, aging or pharmacologic agents act on specific brain neurochemical systems (cholinergic and 
gamma-aminobutyric acid (GABA)) that determine the phenotype, severity and duration of the delirium 
episode.34  
In summary, it has been strongly suggested that the pathophysiological mechanism of delirium involves 
imbalances in several neurotransmitter pathways that lead to the development of delirium.33-35  Imbalances 
occur in the release, synthesis and degradation of GABA, glutamate, acetylcholine, norepinephrine, dopamine 
and serotonin leading to neurological dysfunction.12, 33, 36, 37 Some studies have proposed that these pathways 
are further influenced by metabolic disturbances which often occur during critical illness such as sepsis, 
inflammation, ischaemia and glucose dysfunction. Delirium often emerges when multiple predisposing and 
precipitating risk factors, iatrogenic or environmental factors and metabolic disturbances converge.33-35 
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1.8 Recognition and screening  
Delirium after cardiac surgery is a known complication that is associated with increased morbidity and 
mortality.13,50 Early recognition, increased screening and early intervention have been shown to improve 
patient outcomes.38, 39 The gold standard for delirium diagnosis is an interview conducted by a trained clinician 
(psychiatrist) using the DSM-IV criteria.37-40 However, the feasibility of this approach in the clinical setting 
makes it impractical.38 Arguably, critical care nurses are ideally placed to recognise and screen for delirium 
early, particularly in this patient cohort.38-40 A number of delirium assessment tools have been developed to 
assist nurses in screening and assessment.41 The Society of Critical Care Medicine Pain, Agitation and 
Delirium (PAD) guideline advocates for frequent monitoring to occur at least once per shift (every 8 – 12 
hours) using a valid assessment tool.38, 39, 42-44 Five assessment tools have been reviewed by The Society of 
Critical Care Medicine; the Confusion Assessment Method for ICU (CAM-ICU), Intensive Care Delirium 
Screening Checklist (ICDSC), Cognitive Test for Delirium (CTD), Delirium Detection Score (DDS) and the 
Nursing Delirium Screening Scale (Nu-DESC).43 The CAM-ICU and ICDSC are both used for identifying 
delirium in both mechanically ventilated and self-ventilating patients and have been validated.43 Studies 
conducted to compare assessment tools have revealed that the CAM-ICU may be highly sensitive while the 
ICDSC may have greater specificity.12, 18, 45, 46 However, more recent studies suggest that the two assessment 
tools perform differently in different populations and settings and that specificity is sometimes better for the 
CAM-ICU than the ICDSC.12, 47 The consensus among experts is that both instruments are excellent 
screening tools and either will provide better assessment than other instruments or an unstructured clinical 
assessment.12, 47  
1.9 Management and treatment 
Due to the complex and multifactorial nature of delirium, treatment and management is challenging.1, 40, 48 
The duration and severity of deliria has short and long-term implications.13, 25, 49 There is strong evidence 
indicating that prolonged delirium is associated with elevated Sequential Organ Failure Assessment (SOFA), 
Acute Physiology and Chronic Health Evaluation (APACHE) II and Therapeutic Intervention Scoring System 
(TISS) 28 scores, indicating a progression of organ insufficiency, and increased risk of morbidity and 
mortality.13, 50 Unresolved delirium increases the risk of experiencing anaemia, falls, pressure injuries, renal 
failure, wound infections, strokes, transient ischemic attacks and pneumonia.25, 49 Management of delirium 
primarily involves identifying and correcting any underlying cause(s) and the aim is to reduce the severity and 
duration of the delirium episode.12, 51 Management strategies are categorised into either non-pharmacological 
or pharmacological interventions. Non-pharmacological strategies are focused towards prevention rather than 




Non-pharmacological intervention refers to any non-drug intervention.40 Often initiated by the bedside nurse, 
non-pharmacological interventions are designed to reduce environmental risk factors and are therefore 
preventative rather than treatment strategies.40 A number of non-pharmacological interventions have been 
attempted including sleep promotion, noise and light management, music therapy, patient re-orientation and 
early mobilisation.40, 43 
Studies conducted to examine the efficacy of non-pharmacological strategies tend to be performed as multi-
component complex interventions such as care bundles or clusters rather than in isolation and have shown 
promising results.40 Inouye et al, 1999 conducted a controlled clinical trial on non-pharmacological multi-
component interventions, reporting a 40% decrease in the incidence of delirium in the target group.52 Similar 
results have been reported in additional studies where non-pharmacological interventions have been studied 
as care bundles and implemented using a multidisciplinary team approach.38, 40, 43, 53, 54 Non-pharmacological 
intervention studies conducted to examine the efficacy of individual interventions are limited. A review 
exploring the potential relationship between sleep deprivation and delirium revealed the mechanism was 
largely unknown and recommended further studies to be conducted with ICU patients rather than non-ICU 
patients.37 More recently, a systematic review was conducted exploring the effectiveness of both 
pharmacological and non-pharmacological interventions on the treatment of delirium in the elderly and 
revealed little evidence of the effectiveness of either for managing the deliria episode.55 
Non-pharmacological care bundles with a multidisciplinary team approach is a widely recommended 
approach outlined in clinical guidelines for the pre-eminent professionals responsible for managing the 
condition.18, 43, 56 Environmental interventions and cognitive-emotional support provided by nurses, general 
medical and psychiatric clinicians are suggested together with supportive measures that minimise the 
exacerbation of the delirium through re-orientation, reassurance and education measures.18 A 
multidisciplinary approach in which care is tailored to meet the patient’s needs is advocated in the National 
Institute for Health and Care Excellence (NICE) quality standards for delirium in adults.56 The Society of 
Critical Care Medicine’s 2013 Pain, Agitation and Delirium (PAD) guideline outlines a multifaceted approach 
to the management of delirium in the ICU setting in which the Awakening and Breathing Coordination, Delirium 
monitoring/management and Early exercise/mobility (ABCDE) care bundle are used.42, 43 The ABCDE care 
bundle includes strategies such as frequent assessment of delirium using a validated tool, treating pain with 
appropriate analgesia, minimising sedation, implementing sedation breaks and encouraging spontaneous 
breathing trials and early mobilisation.42, 43, 57 The PAD guideline also provides an acknowledgement that 
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delirium management in the ICU setting has not been adequately studied and requires further investigation.43, 
57  
Pharmacological interventions 
Pharmacological agents used to manage delirium aim to reduce the severity and duration of the deliria 
episode while preventing the harmful sequelae.58 Like any pharmacological agent, the effectiveness and 
harms of the agent need to be taken into consideration in determining a suitable treatment agent, hence it is 
imperative that clinicians are cognisant of any adverse effects that may emerge.25 
Pharmacological agent induced harms or adverse effects are unfavorable outcomes that can be detrimental 
to recovery and may add a financial burden to the health care system.59 Not every pharmacological agent is 
suitable for every patient. Likewise, postoperative cardiac surgical patients require careful consideration due 
to the myocardial dysfunction and conduction irritability that often presents following cardiac surgery.60 
Conduction irritability and myocardial dysfunction occurs as a result of reperfusion to the heart and there are 
large fluid shifts and inflammation that may lead to haemodynamic instability in the initial postoperative 
period.60, 61 Postoperative cardiac patients are reliant on adequate cardiac output.61-63 Low cardiac output 
impairs cardiac performance leading to tissue and cerebral hypoperfusion and multiorgan dysfunction, 
increasing the risk of death.60-64 
A number of studies have investigated the effectiveness of various pharmacological interventions that include 
adrenergic alpha-2 agonists (e.g., dexmedetomidine, clonidine), sedatives (e.g., propofol and 
benzodiazepines e.g., diazepam, midazolam) and typical and atypical antipsychotics (e.g., haloperidol, 
quetiapine and olanzipine) and have shown mixed results.23 Randomised controlled trials (RCTs) have 
investigated the effectiveness of dexmedetomidine in the prevention of postoperative delirium in adult patients 
after cardiac surgery.65-70 Prophylactic low dose dexmedetomidine (i.e. 0.1micrograms/kg/hr started 
intraoperatively) as a continuous infusion in the treatment group resulted in significant decreases in the 
occurrence of delirium after surgery during the first seven days.69 Another RCT comparing dexmedetomidine 
with propofol sedation in reducing delirium after cardiac surgery showed that dexmedetomidine sedation 
reduced the incidence, delayed the onset and shortened the duration of the delirium episode.66 Other 
pharmacological agents explored include a study comparing ondansetron with haloperidol for the treatment 
of delirium following cardiac surgery, showing that both ondansetron and haloperidol had good delirium 
controlling effect but lacked statistically significant differences.71 Many of these primary studies evaluated the 
benefits of two pharmacological interventions or a placebo but excluded the assessment of pharmacological 
harms, adverse or unintended side effects. 
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1.10 Scope and state of current literature on the topic 
A preliminary search of the JBI Database of Systematic Reviews and Implementation Reports, Cochrane 
Library, PubMed, EPISTEMONIKOS and PROSPERO found that there are existing systematic review 
protocols and finalised systematic reviews on the effectiveness of pharmacological interventions for the 
treatment of delirium in adult patients in ICUs.72-78 The focus of many of these published systematic reviews 
has been on preventing postoperative delirium through the preoperative or perioperative administration of 
pharmacological agents rather than treatment of postoperative delirium.74, 78, 79 One published systematic 
review examined both prevention and treatment of delirium in the postoperative cardiac surgical patient and 
found inconclusive evidence to support the treatment of delirium using pharmacological agents.75 These 
reviews have not used the exact inclusion criteria, search strategy or critical appraisal and synthesis 
approaches that were used in this systematic review. Nor have they systematically examined both 
effectiveness and harms using standardised appraisal tools. The reporting in these reviews was found to be 
incomplete where benefits of the intervention were emphasised while the assessing and reporting of harms 
was inadequately reported.74-76, 78-80  
1.11 Relationship between the existing literature and rationale for conducting the 
systematic review 
Well conducted clinical trials and systematic reviews provide the best available evidence for clinicians to 
identify the most suitable pharmacological agent for their patient. The preliminary search identified poor 
reporting about harms associated with pharmacological agents used in the treatment of delirium following 
cardiac surgery. The systematic review that underpins this thesis differed from previously published reviews 
as it examined both effectiveness and harms using standardised appraisal instruments. Additionally, it was 
more comprehensive in primary and secondary outcomes compared with previously published reviews.72, 75-
77, 81, 82 Therefore, the aim was to address the poor reporting about harms and provide a balanced review of 
both effectiveness and harms related to the pharmacological agents used to treat postoperative cardiac 
surgical delirium so that clinicians are better informed when treating delirium in this cohort of patients.  
 
In this chapter the topic of interest, the effectiveness and harms of pharmacological interventions in the 
treatment of delirium in adults treated in the ICU following cardiac surgery were introduced. This chapter also 
contained an overview of the existing literature with a rationale for conducting a systematic review. In the next 
chapter EBHC, evidence synthesis and systematic review methodology are introduced. 
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CHAPTER 2: METHODOLOGY 
_____________________________________________________________________________________ 
In this chapter of the thesis the methodology used in the systematic review is introduced. An overview of 
evidence-based healthcare (EBHC) and the Joanna Briggs Institute (JBI), including its model of EBHC is 
provided. Following this, there is a discussion on evidence synthesis and the systematic review, Levels of 
Evidence, and the GRADE (Grading of Recommendations Assessment, Development and Evaluation) 
approach.  
 
Evidence-based healthcare (EBHC) 
The origins of evidence-based practice extend back to the mid-19th century, Paris.83 During this time Pierre 
Louis (1787-1872), a meticulous clinician, ‘pre-formal’ epidemiologist and researcher became an important 
precursor of modern epidemiology and evidence-based practice when he undertook the first known 
experiment of early bloodletting for the treatment of pneumonia.84, 85 Louis understood the importance of 
sharing his findings, publishing several monographs during his career.85 This work was further developed by 
James Lind (1716-1794), a Scottish surgeon who conducted the first systematic clinical trial looking into the 
cause and treatment of scurvy in British sailors.86 Like Louis, Lind was a prolific writer, sharing his research 
findings in a bid to seek understanding and change practice as a result.86 During the 20th century this work 
continued and in 1991 David Sackett and his team at McMaster University, Canada coined the term ‘evidence-
based medicine’.87  
Evidence-based medicine (EBM) is defined as “the conscientious, explicit, and judicious use of current best 
evidence in making decisions about the care of the patient” 83(p.71) An increasing awareness of the weaknesses 
of standard clinical practices and their impact on both quality and cost of patient care was the impetus for 
EBM.87 Clinical decision-making was once derived through expert opinion, experience and authoritarian 
judgement.87 This novel approach was to bring more certainty to clinical decision-making and to help doctors 
find the information to ensure that they provide optimal management for their patients.88 The practice of EBM 
involved integrating individual clinical expertise with the best available external clinical evidence from 
systematic research.83 Clinical expertise referred to the proficiency and judgement of practicing clinicians 
while external clinical evidence referred to a wide variety of relevant research “that can inform , but can never 
replace, individual clinical expertise.”83(p.72) “It is the clinical expertise that decides whether the external 
evidence applies to the individual patient and if so, how should it be integrated into a clinical decision”. 83(p.72)  
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The primary roots of EBM were originally grounded in medicine, as EBM evolved so to have the professional 
standards of other health disciplines whose practices are now based on the best available evidence.89 Nursing 
was no exception. During the 1980s, nursing became a professional entity that saw nurse training move from 
a hospital-based to a university-based education programme. At this time, research utilisation was 
incorporated into the nursing profession that focused on translating research findings into clinical practice.89 
To prepare nurses for professional practice, education standards at baccalaureate, master’s and doctoral 
level all required the integration of best evidence, clinical judgment, interprofessional perspectives, and the 
patient’s preferences research.89 This lead to the evolution of EBM into the EBHC model where it has been 
utilised by other health disciplines with the aim to provide healthcare that is supported by evidence.89  
Contemporary understandings of EBHC are based on the need for all health practitioners to practice in ways 
that are supported by the most up-to-date evidence or knowledge available.90 Accessing the best available 
evidence to assist in clinical decision-making regarding the care of individual patients or the delivery of 
healthcare services is the fundamental basis of EBHC. All clinical decisions should be based on the best 
available evidence, the individual patient preference, the context in which the care is being delivered and the 
professional judgement and expertise of the health clinician.90  
Evidence is a complex connotative concept with multiple meanings.83 When applied to healthcare, evidence  
may be defined as “the basis of belief; the substantiation or confirmation that is needed in order to believe 
that something is true”.90 The most reliable type of evidence is evidence that has been generated by either 
quantitative or qualitative research.91 Quantitative research seeks to establish a relationship between two or 
more variables with the strength and significance of those relationships being assessed using statistical 
models.91 The strength of the quantitative evidence lies in its validity and reliability; results must be repeatable 
and consistent, yielding the same results or answers time after time.91 On the other hand, qualitative research 
takes a humanistic approach that seeks to analyse the human experiences and cultural and social 
phenomena.91 Qualitative research incorporates a range of qualitative research methods such as 
ethnography, phenomenology, qualitative inquiry, action research, discourse analysis and grounded theory.91  
Determining the ‘best available evidence’ remains controversial as not all evidence is the same.92 The 
hierarchy of evidence pyramid, a core principle of EBHC places the highest form of evidence at the top of the 
pyramid.92 Traditionally, systematic reviews are considered the highest form of evidence while randomised 
controlled trials (RCTs) are considered to be the ‘gold standard’ that offers the best approach to generate 
evidence of effectiveness.92 Systematic reviews offer the highest form of evidence as they aim to provide an 
unbiased, comprehensive and rigorous analysis of all available evidence.91, 93 Randomised controlled trials 
hold their position by the nature of ‘randomisation’, reducing the risk of bias and examining cause-and-effect 
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relationships between interventions and outcomes.93 Sackett et al, 1996 argued that reviewing evidence for 
EBM requires a bottom up approach, an approach that integrates the best external evidence with individual 
clinical expertise and patients’ choice. 83(p72) Since this time, a number of organisations involved in the 
development and dissemination of evidence-based research and reviews have been established. 
Organisations such as the JBI, Cochrane Collaboration and Campbell Collaboration have been established 
to assist health professionals to improve health outcomes by providing the best available evidence to inform 
clinical decision making.93 
The JBI approach to EBHC 
The JBI takes an inclusive approach to what constitutes evidence, being that of feasibility, appropriateness, 
meaningfulness and effectiveness of healthcare practice (FAME).91 The JBI regard the “findings” of qualitative 
research studies, text derived from opinion, experience and expertise can also be regarded as the “best 
available” evidence.”91(p.211) The Institute’s unique approach to EBHC was first published in 2005 as a 
conceptualised framework that aimed at improving health outcomes.91 This framework is referred to as the 
JBI Model of EBHC (referred to hereafter as the ‘JBI Model’).91 The JBI model is based on the Institute’s 
approach to translating the best available evidence into best practice in the appropriate healthcare setting. 90, 
94 A recent update of the JBI Model was undertaken in 2016 and is presented in Figure 1.95 
 
 
Figure 1: The JBI Model 
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The JBI Model is a cyclical process.91, 95 The ‘Central Circle’ of the model denotes the ‘Pebble of Knowledge’, 
a conceptualisation of EBHC that seeks evidence from the literature to answer questions on feasibility, 
appropriateness, meaningfulness and effectiveness of a specific intervention for a particular condition.95 The 
five ‘Inner Wedges’ depict component parts of the JBI Model that include: global health, evidence generation, 
evidence synthesis, evidence transfer and evidence implementation.95 Global health care needs are identified 
by clinicians or patients/consumers.95 Evidence that is feasible, appropriate, meaningful and effective is then 
generated to address those needs identified.95 That evidence is then collated where the results are appraised, 
synthesised and transferred to the healthcare setting where it can be utilised by health professionals to 
improve health outcomes, health systems and professional practice.95 The ‘Outer Wedges’ depict the 
operational components of the JBI Model.95 The focus of this thesis is on quantitative evidence and sits within 
the evidence synthesis wedge as it involves the conduct of a systematic review on the effectiveness and 
harms of pharmacological interventions in the treatment of delirium in adults in intensive care units post 
cardiac surgery. 
Evidence synthesis 
According to the JBI Model, evidence synthesis is defined as “the evaluation or analysis of research evidence 
and opinion on a specific topic to aid in decision-making in healthcare”.90(p.211) Informing practice requires a 
review of all relevant evidence to be undertaken, where the results are collated, conclusions are drawn upon 
and recommendations are made.90 There have been fourteen types of reviews identified so far with the most 
common being literature reviews, scoping reviews and systematic reviews.96 97While they all have their merits, 
literature reviews provide an examination of recent or current literature that covers a wide range of subjects 
at various levels of completeness and comprehensiveness.96 Scoping reviews provide a preliminary 
assessment of the potential size and scope of available research literature and aims to identify the nature and 
extent of research evidence.96 Systematic reviews remain the core of evidence synthesis; they are essentially 
a summary of knowledge and a collation of the findings about a specific question/s.90, 96  
The systematic review 
By definition, “systematic reviews critically appraise and formally synthesise the best existing evidence to 
provide a statement of conclusion that answers specific clinical questions.”98(p. 2761) The nature of the clinical 
question will determine the type of evidence the systematic review will consider: quantitative, qualitative,  
mixed methods, an evaluation of health economics or textual evidence.91 It is generally accepted that 
systematic reviews follow seven steps: 
1. Research question: Formulating the research question that summarises the objective of the review 
is the first step.91 For quantitative reviews, the research question identifies the inclusion criteria for 
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considering studies and should make reference to the review’s intended population, intervention, 
comparator and outcomes (PICO).91 
2. Research protocol: Once the research question has been generated, the research protocol is 
developed91. The protocol pre-defines the objectives and methods of the systematic review, outlining 
the approach for which the review will be conducted and reported and allows for transparency of the 
review process.91 Once developed, ideally  the protocol is then subjected to peer-review prior to the 
commencing the review.91 A requirement of a JBI systematic review is an a priori published protocol.99 
3. Comprehensive search strategy: The literature search aims for exhaustive, comprehensive searching 
to identify all research relating to the review question.91 The JBI approach aims to identify both 
published and unpublished records utilising a three-stage search process.91 
4. Critical appraisal: The aim of a systematic review is to synthesise the best available evidence; hence 
the methodological quality of included studies needs to be appraised using validated checklists or 
tools to assess for biases.91 Quality assessment is undertaken by two independent reviewers to 
determine inclusion/exclusion of studies.91 
5. Data extraction: Details regarding the participants, interventions, comparators and outcomes are 
extracted from the included studies.91 Use of a standardised extraction tool aims to minimise errors 
in extracting data.91 
6. Data synthesis: Involves the analysing of results, which can either be descriptive (narrative summary) 
or statistical (meta-analysis).91 A meta-analysis can be conducted when results of similar 
(homogeneous) individual studies are combined to determine an overall effect of a particular 
intervention.91 A meta-analysis permits a summary about the effect size of an intervention compared 
to a control.91 However, when there is diversity or variation (heterogeneous) between the primary 
studies a narrative summary is provided, including the reasons of the heterogeneity and the 
inappropriateness of combining the data statistically.91 The method of data synthesis will always 
influence the findings of the systematic review.91 
7. Interpretation of results: Data can then be analysed and interpreted, including the strengths and 
weaknesses of the included studies.91 The method of data synthesis will always influence the findings 
of the systematic review.91 Conclusions should be based on the available evidence, and 
recommendations for practice and future research are provided at the end.91 
The aforementioned steps of conducting a systematic review are generally accepted across the systematic 
review community.90, 100 The Cochrane Collaboration and the JBI methodology are predominantly used to 
conduct quantitative systematic reviews for the effectiveness of an intervention.90, 100 Systematic reviews are 
often referred to when decisions around clinical practice are required.90 However, there are limitations 
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associated with conducting a systematic review, such as the time and resources it takes to complete a review. 
Despite the best efforts of investigators, the evidence and recommendations contained within the review may 
be outdated by the development and publication of new evidence during this process. In addition, systematic 
review are by nature focused so that they address very narrow clinical questions and may not assist clinical 
decision making as a result.90 
Levels of evidence and the grading of recommendations 
Systematic reviews provide a comprehensive summary of the evidence that addresses a clinical question and 
are considered to be the highest level of evidence. However, evidence is required to be ranked according to 
its quality and deciphering the quality of the evidence can be challenging and complex. There are a number 
of hierarchy (pyramid) systems available that focus on placing the highest quality study designs at the top 
with the weakest at the bottom.92 Nevertheless, guidelines are inconsistent on how they rate quality of 
evidence and grade strength of recommendations.101  
In the early 2000s, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
working group was established.92 This working group developed a grading of evidence and recommendation 
system (referred to as the GRADE approach) that was launched in March 2014 and has since been endorsed 
by many EBHC organisations.102, 103 The GRADE approach is not solely focused on study design but takes 
into consideration numerous other factors, an approach which challenges the pyramid concept.102 This 
approach assists in collating the results of quantitative research, rating the quality of evidence for outcomes 
and clearly presenting the results in an evidence table, such as a Summary of Findings table (SoF). The 
factors that GRADE considers include risk of bias, inconsistency, indirectness, imprecision, publication bias, 
effect sizes, dose-response relationships and confounders of findings (Table 1).102  The included evidence in 
the systematic review is then ranked out of a possible four levels (High, Moderate, Low and very Low) (Table 
2).102 The evidence is initially pre-ranked according to the study design; high quality for RCTs and low quality 




Table 1: Application of GRADE quality of evidence in the GRADE approach 
Quality Rating quality of results/findings 
Risk of bias Assessed based on the limitations in study design to downgrade the quality of 
evidence for the outcome into: 
(a) Not serious (b) serious (c) very serious 
Inconsistency Assessed based on the results being consistent enough across the studies to 
downgrade the quality of evidence into: 
(a) Not serious (b) serious (c) very serious 
Indirectness Assessed based on whether the evidence directly answers the healthcare 
question asked being enough to downgrade the quality of the evidence for the 
outcome into: 
(a) Not serious (b) serious (c) very serious 
Imprecision Assessed based on the results being precise or not enough to downgrade the 
quality of evidence for the outcome into: 
(a) Not serious (b) serious (c) very serious 
Publication bias Assessed based on the probability of publication bias serious enough to 
downgrade the quality of evidence for the outcome into:  
(a) Undetected (b) strongly suspected 
Large effect Assessed based on the magnitude of effect being large or very large, and if so 
to upgrade the quality of evidence for the outcome into: 
(a) No (b) large (c) very large 
Plausible confounding Assessed based on the evidence found of studies that the influence of all 
plausible residual confounding would reduce a demonstrated effect or suggest 
a spurious effect to either downgrade or upgrade the quality of evidence for the 
outcome into: 
(a) No (b) would reduce a demonstrated effect (c) would suggest a 
spurious effect 
Dose response gradient Assessed based on the presence of evidence of dose-response gradient 
upgrade the quality of evidence for the outcome into: 
(a) No (b) yes 





Table 2: GRADE ratings and their interpretation 




We are very confident that the true effect lies close to that of the estimate 
effect. 
Ο Moderate 
We are moderately confident in the effect estimate: the true effect is 
likely to be close to the estimate of the effect, but there is a possibility 
that it is substantially different. 
ΟΟ Low 
Our confidence in the effect estimate is limited: the true effect may be 
substantially different from the estimate of effect. 
ΟΟΟ Very low 
We have very little confidence in the effect estimate: the true effect is 
likely to be substantially different from the estimate of effect. 
***Table taken from the GRADE Handbook, available at https://gdt.gradepro.org/app/handbook/handbook.html 
 
The evidence can then be either downgraded or upgraded based on the aforementioned factors.102 
Downgrading occurs as a result of risk of bias, inconsistency, indirectness of evidence, imprecision of results 
and publication bias.102 Upgrading occurs as a result of large magnitude of effect, dose response and 
plausible confounding factors.102 Synthesising the findings pertaining to systematic reviews of effectiveness 
is presented in a SoF table, which is created from the GRADEpro website (http://gradepro.org). 
 
In this chapter, the methodology used in the systematic review was introduced. An overview of EBHC and 
JBI, including its model of EBHC was provided. Following this, there was a discussion on evidence synthesis 
and the systematic review, Levels of Evidence, and the GRADE approach. The next chapter outlines the 
systematic review methods including eligibility criteria, search strategy, study selection, critical appraisal, data 




CHAPTER 3: SYSTEMATIC REVIEW METHODS 
_____________________________________________________________________________________ 
The systematic review methods are outlined in chapter three including the review eligibility criteria, search 
strategy, study selection process, how the studies were critically appraised, data extraction and data synthesis 
methods. This systematic review was conducted in accordance with the Joanna Briggs Institute methodology 
for systematic reviews of effectiveness evidence91 and in accordance with an a priori protocol.99 (PROSPERO 
Registration Number: CRD42018100124). 
 
Inclusion criteria 
Types of participants 
This review included participants who were adults older than 16 years, who were treated in a cardiothoracic 
ICU following cardiac surgery and who were identified as having delirium during their postoperative recovery 
period. This was regardless of ethnicity, gender and with or without co-existing psychiatric or neurological 
conditions. Cardiac surgery included any type of cardiac surgery (such as, but not limited to, coronary artery 
bypass [CABG], valvular repairs/replacements and transcatheter aortic valve implantation [TAVI]).  
Types of intervention 
Studies in which any pharmacological intervention for the treatment of delirium in adult patients treated in the 
ICU after cardiac surgery was evaluated were considered. Studies that reported any pharmacological 
intervention were considered for inclusion regardless of dosage, intensity or frequency of administration. The 
pharmacological interventions considered for inclusion were: atypical and typical antipsychotics such as, but 
not limited to haloperidol, quetiapine and olanzapine, benzodiazepines such as, but not limited to diazepam 
and midazolam, sedatives such as, but not limited to propofol and alpha-agonists such as, but not limited to 
dexmedetomidine and clonidine. 
Comparator 
Studies that compared the intervention with any other pharmacological intervention for the treatment of 
delirium in patients who were treated in the ICU after cardiac surgery from the previously mentioned classes 
of drugs were considered. No limitations were placed on drug classification, dosage of the medications, 





Studies that included any number of the following primary or secondary outcomes were considered:  
Primary outcomes: 
• Mortality due to all causes (ICU mortality and post discharge mortality such as but not limited to 30-
day mortality) 
• Duration of delirium regardless of the measurement approach used  
• Severity of delirium regardless of the assessment approach or tools used 
• Frequency of the use of physical restraints  
• Patients’ quality of life during ICU stay as reported by healthcare professionals or family members, 
regardless of the assessment approach or measurement tools used  
• Family members’ satisfaction with delirium management provided regardless of the assessment 
approach or measurement tools used 
• The duration and severity of patient aggressive or violent episodes against healthcare staff, other 
patients and family members or other persons in contact with the patient, regardless of the 
assessment approach or measurement tools used 
• The number and severity of patient falls regardless of the assessment approach used 
• The number and severity of patient accidental self-harm events such as but not limited to 
unintentional extubations, accidental removals of invasive lines, catheters/cannulas regardless of the 
assessment approach used 
• Harms related to pharmacological interventions such as, but not limited to adverse events and side 
effects, regardless of the assessment approach used 
• Harms related to ‘over sedation’ such as prolonged time to rouse when sedative medications are 
ceased, wean from mechanical ventilation and be deemed ready for discharge from ICU, regardless 
of the assessment approach used 
• For the purposes of this systematic review, the term ‘harms’ refers to the totality of all possible 
consequences of an intervention or therapy such as side effects, adverse events, adverse reactions, 
adverse drug reactions etc., as defined in the CONSORT Statement: the Statement extension for 






• ICU length of stay - number of days from admission to time of discharge from ICU 
• Length of hospital stay after ICU discharge – number of days from the time of discharge from ICU to 
the time of discharge from the hospital 
• Total hospital length of stay – number of days from admission to time of discharge from the hospital 
• Need for additional medication used for management of the delirium regardless of the approach used 
for the assessment for the need, otherwise referred to as rescue therapy or medication that is 
additional to the pharmacological agent being trialed 
• Use of additional medication for the management of delirium regardless of the approach used for the 
assessment for the use. This refers to the need for additional doses of the pharmacological agent 
being trialed 
Types of studies 
Both experimental and non-experimental study designs were considered such as RCTs, non-RCTs, quasi-
experimental, before and after studies, observational, prospective and retrospective cohort studies and 
analytical cross-sectional studies for inclusion. We considered for inclusion firstly randomized experimental 
studies as they provide, by randomization, for both effectiveness and harms, less biased evaluations of effects 
compared to other study designs. In the absence of randomized experimental studies, we considered non-
randomized controlled trials and quasi-experimental studies. In the absence of experimental and quasi-
experimental studies we would have considered analytical observational studies.  
Search strategy 
The search strategy aimed to find both published and unpublished studies. A three-step search strategy was 
used. An initial limited search of PubMed and CINAHL was undertaken, followed by analysis of the text words 
contained in the title and abstract and the index terms used to describe the articles. A second search using 
all identified keywords and index terms was undertaken between the 21st and 25th September 2017. Thirdly, 
the reference lists of all citations retrieved for full text screening were searched for additional studies prior to 
their appraisal. Only studies published in English were considered for inclusion in this review. There was no 
date limit or geographical restrictions on the search strategy. The search was repeated on the 18 November 
2018 to verify currency. 
To ensure that the search was extensive an additional hand search of journals relevant to the specialised 
topic was undertaken. The journals selected were determined by the review team and based on the most 
commonly accessed national and international intensive care and cardiothoracic journals by clinicians. An 
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initial time limit of five-years (2012 – 2017) was set for the initial hand search, with a repeat search carried 
out from September 2017 until September 2018. This gave an overall hand search period of six years. The 
decision to limit the number of journals and time period for hand searching was based on the limited availability 
of resources. A research librarian assisted throughout this process. The full search strategies are presented 
in Appendix I.  
Information sources 
The databases searched were: 
• PubMed  
• Embase 
• CINAHL 
• Web of Science  
• Cochrane Central Register of Controlled Trials  
• Scopus 
• EPISTEMONIKOS.  
The search for unpublished studies included: 
• Australian New Zealand Clinical Trials Registry 
• ClinicalTrials.gov  
• Clinical Trials in New Zealand 
• ProQuest Dissertation and Theses.  
A hand search for primary studies published in relevant journals (2012 – 2018) for the last six years included:  
• Australian Critical Care  
• Journal of Cardiothoracic Surgery  
• American Journal of Respiratory and Critical Care Medicine 
• Intensive Care Medicine 
• Critical Care Medicine 
A hand search for primary studies used in relevant clinical practice guidelines included: 
• American Society of Critical Care Medicine  
• American Society of Critical Care Nurses  





Following the search, all identified citations were loaded into EndNote X7 (Clarivate Analytics, PA, USA) and 
duplicates removed. Titles and abstracts were screened by two independent reviewers for assessment 
against the inclusion criteria. The full text of potentially eligible studies was retrieved and assessed in detail 
against the inclusion criteria by two independent reviewers. The details of studies that met the inclusion criteria 
were imported into the Joanna Briggs Institute System for the Unified Management, Assessment and Review 
of Information (JBI SUMARI, The Joanna Briggs Institute, Adelaide, Australia). Full text studies that did not 
meet the inclusion criteria were excluded and reasons for their exclusion are provided in Appendix II. Any 
disagreements that arose between the reviewers were resolved through discussion, or with a third reviewer. 
Assessment of the methodological quality 
As originally outlined in the review protocol,99 eligible studies selected for retrieval were critically appraised 
by two independent reviewers at the study level using the standardised critical appraisal instrument from JBI 
for RCTs.93 The McMaster Quality Assessment Scale of Harms (McHarm) for primary studies was also used 
to appraise the quality of the studies exploring the pharmacological harms, adverse or unintended effects.105, 
106 Studies were included regardless of methodological quality. There were no disagreements between the 
two reviewers therefore a third reviewer was not required. 
Data extraction 
Data was extracted from studies included in the review by two independent reviewers, using the standardised 
JBI data extraction tool.93 The data extracted included specific details about the interventions, populations, 
study methods and outcomes of significance to the review question and objective. There were no 
disagreements between the two reviewers therefore a third reviewer was not required. 
Data synthesis 
A meta-analysis was not performed as there were significant differences between interventions and outcome 
measures (clinical heterogeneity) and designs (methodological heterogeneity). Thus, the findings have been 
presented in narrative form, including tables to aid in data presentation.  
Assessing certainty in the findings 
The GRADE approach for grading the certainty of evidence was followed107 and a Summary of Findings (SoF) 
was created using GRADEPro GDT 2015 (McMaster University, ON, Canada). The SoF presents the 
following information where appropriate: absolute risks for the treatment and control, estimates of relative 
risk, and a ranking of the quality of the evidence based on the risk of bias, directness, heterogeneity, precision 
and risk of publication bias of the review results. The primary outcomes reported in the SoF include mortality, 
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duration, severity or presence of delirium, harms related to pharmacological interventions and hospital/ICU 
length of stay (LoS). 
 
In this chapter the methods used in the underlying systematic review were outlined, including the eligibility 
criteria, search strategy, study selection process, how the studies were critically appraised, data extraction 
and data synthesis methods. In the next chapter, the search results, reasons for excluding studies, 
assessment of the methodological quality and an overview of the results of the three papers included in the 




CHAPTER 4: RESULTS 
_________________________________________________________________________ 
In chapter four, the findings of the systematic review conducted to evaluate the effectiveness and harms of 
pharmacological interventions in the treatment of delirium following cardiac surgery are provided. A detailed 
description of the search results, the study selection process and the assessment of methodological quality 
is presented which is followed by the characteristics of the included studies. Finally, a narrative synthesis of 
the results organised by outcome is provided.  
 
Description of search results and study selection process  
The initial search was undertaken in September 2017 and identified a total of 3201 potentially relevant 
citations using the search strategies developed for each database (Appendix I), plus 227 records identified 
through other sources. The search was updated in November 2018 and limited to 12 months, which identified 
1019 potentially relevant citations. Between the two search dates, a total of 4447 records were identified. Of 
the 4447 citations, 430 were excluded as duplicates. Of the remaining citations, 3802 were excluded after 
examination of the title and abstract. A full-text review of 215 papers was conducted, 205 were immediately 
excluded for not fulfilling the inclusion criteria (reasons for exclusion are presented in Appendix II). The 
remaining 10 studies were then assessed by two independent reviewers. One RCT was subsequently 
excluded on the basis of treating subsyndromal delirium rather than hyperactive delirium.108 One abstract and 
five studies were excluded due to higher-quality studies being located,3,109-113 One cohort study109 was 
identified as a precursor to an included RCT.71 The methodological quality of the remaining three studies was 









































































Records identified through database 
searching 
 
(n = 4220) 




(n = 227) 
Records after duplicates removed 
(n = 430) 
Records screened 
(n = 4017) 
Records excluded based on title 
and abstract 
(n = 3802) 
Full-text studies assessed for 
eligibility 
(n = 215) 
Full-text studies excluded, with 
reasons 
(n = 212) 
Not original research  (n = 91) 
Ineligible population  (n = 10) 
Ineligible intervention  (n = 84) 
Ineligible outcome  (n = 19) 
Ineligible study design  (n = 8) 
 
 
Studies assessed for 
methodological quality 
(n = 3) 
Studies included in the 
systematic review 
(n = 3) 
Studies excluded following 
assessment of methodological 
quality 
(n = 0) 
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Methodological quality of included studies 
Two independent reviewers carried out critical appraisal of the three included studies using the JBI critical 
appraisal tool for RCTs.93 The JBI critical appraisal tool contains thirteen questions. Responses are either a 
yes, no or unclear. Across the three studies the majority of responses were ‘unclear’ (n=28), the remainder 
were ‘yes’ (n=11) signifying low methodological quality (Table 3). The low methodological quality occurred 
mainly as a result of information lacking related to true randomisation, allocation concealment, blinding of 
participants, clinicians and assessors, follow-up, intention-to-treat analysis, reliability of measured outcomes 
and statistical analysis procedures where information was unclear for all three studies. For example, the study 
design in two studies was reported as ‘randomized with participants randomly allocated into two groups’70, 71 
while the third study was reported as a ‘prospective, randomized, double-blinded study’114 however no details 
regarding the actual procedure for randomisation were provided. This may have impacted the internal validity 
of the studies or the authors simply omitted these details in their published papers. Efforts to elicit further 





Table 3: Critical appraisal results of eligible studies using the JBI Critical Appraisal Checklist for Randomised 
Controlled Trials 
Study Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 
Atalan et al.112 U U Y U U U Y U U Y U U Y 
Tagarakis et al.71 U U Y U U U U U U Y U U Y 
Yapici et al.70 U U Y U U U Y U U Y U U Y 
Total number Y 0 0 3 0 0 0 2 0 0 3 0 0 3 
 
Y = Yes; N = No; U = Unsure; JBI Critical appraisal checklist for randomized controlled trials: Q1 = Was true 
randomization used for assignment of participants to treatment groups?; Q2 = Was allocation to treatment 
groups concealed?; Q3 = Were treatment groups similar at baseline?; Q4 = Were participants blind to 
treatment assignment?; Q5 = Were those delivering treatment blind to treatment assignment?; Q6 = Were 
outcome assessors blind to treatment assignment?; Q7 = Were treatment groups treated identically other 
than the intervention of interest?; Q8 = Was follow-up complete and if not, were differences between groups 
in terms of their follow-up adequately described and analyzed?; Q9 = Were participants analyzed in the groups 
to which they were randomized?; Q10 = Were outcomes measured in the same way for treatment groups?; 
Q11 = Were outcomes measured in a reliable way?; Q12 = Was appropriate statistical analysis used?; Q13 
= Was the trial design appropriate, and any deviations from the standard RCT design (individual 
randomization, parallel groups) accounted for in the conduct and analysis of the trial? 
 
The McMaster Quality Assessment Scale of Harms (McHarms) appraisal tool contains fifteen questions to 
guide the appraisal of harms data collection and reporting.105, 106 The McHarms appraisal tool insures harms 
reporting in RCTs meets the standards and recommendations defined in the CONSORT Statement: the 
Statement extension for harms.104 The questions relate to assessing if harms were pre-defined using 
standardised definitions, if serious or severe events occurred, if deaths occurred, how the harms data was 
collected, who collected the harms data and their training in harms data collection, the timing and frequency 
of harms data collection, what harms data collection tools were used as well as follow-up. Responses were 
either ‘yes’, ‘no’ or ‘unclear’. For all three studies the majority of responses were ‘no’ (n=41), only two were 
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‘yes’ (n=2) with the remaining two ‘unclear’ (n=2) signifying that the overall quality of harms reporting was low 
(Table 4). 
Only one study114 reported the number of deaths in each study arm,114 however no further details were 
provided relating to the cause of the deaths. In the other two studies, mortality rates were not provided and 
reasons for excluding this information were not provided. Yapici et al. was the only study that reported the 
timing and frequency of data collection. However, it was difficult to substantiate if the timing and frequency of 
data collection was an a priori intention to monitor and report harms. Appraisal of the studies revealed that 
the study publications did not clearly report the methods of identifying harms, the incidence of the harms or 
potential harms related to the study methodology or interventions. In all three studies, no information was 
provided relating to using standardised pre-defined harms definitions, seriousness of events, mode of harms 
data collection (active or passive), who collected the data, assessor training or background, standardised 
data collection checklists, or what events were considered to be drug related harm. Additionally, efforts to 





Table 4: Critical appraisal results of eligible studies using the McMaster quality assessment scale of harms 
(McHarms) critical analysis  
Study Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 
Atalan et al.114 N N N Y N N N N N N N N N N N 
Tagarakis et al.71 N N N N U N N N N N N N N N N 
 Yapici et al.70  N N N N U N N N Y N N N N N N 
Total number Y  0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 
 
Y = Yes; N = No; U = Unsure; McMaster Quality assessment scale of harms (McHarms) critical analysis tool: 
Q1 = Were the harms PRE-DEFINED using standardised or precise definitions?; Q2 = Were SERIOUS events 
precisely defined?; Q3 = Were SEVERE events precisely defined?; Q4 = Were the number of DEATHS in 
each study group specified OR were the reason(s) for not specifying them given?; Q5 = Was the mode of 
harms collection specified as ACTIVE?; Q6 = Was the mode of harms collection specified as PASSIVE?; Q7 
= Did the study specify WHO collected the harms?; Q8 = Did the study specify the TRAINING or 
BACKGROUND of who ascertained the harms?; Q9 = Did the study specify the TIMING or FREQUENCY of 
collection of the harms?; Q10 = Did the author(s) use STANDARD scale(s) or checklist(s) for harms 
collection?; Q11 = Did the author(s) specify if the harms reported encompass ALL the events collected or a 
selected SAMPLE?; Q12 = Was the TOTAL NUMBER of participants that withdrew or were lost to follow-up 
specified for each study group?; Q13 = Was the TOTAL NUMBER of participants affected by harms specified 
for each study arm?; Q14 = Did the author(s) specify the NUMBER for each TYPE of harmful event for each 
study group?; Q15 = Did the author(s) specify the type of analyses undertaken for harms data? 105  
 
Consensus among the reviewers was to include all three studies, despite their low methodological quality 
both in terms of conduct and reporting. This decision was made as there were a limited number of RCTs that 




Characteristics of the included studies 
In this section, we present a narrative synthesis of the characteristics of included studies. Details related to 
methods, participants’ characteristics, interventions, comparators and outcomes reported by the authors are 
presented in the table of included studies in Appendix III. 
Research design 
This systematic review included three RCTs.70, 71, 114  
Sample size 
A total number of 205 participants who were treated for postoperative delirium after cardiac surgery were 
included. Sample sizes ranged from 53 to 80 participants, with 53 114, 72 71 and 80 70 participants identified in 
each study.  
Setting, publication country and characteristics of study participants 
The three included studies were published between 2010 and 2013. The setting, country and city where the 
included studies were conducted as well as the characteristics of participants, including the mean and 




















Age of sample 
Intervention 
group 
Mean ± SD 
Comparator 
group 
Mean ± SD 











Delirious adult patients who 
had undergone cardiac 
surgery ± cardiopulmonary 
bypass and initially admitted 
into the ICU. 
 
65.74 ± 9.67 
 
66.00 ± 8.39 















Adult patients who 
developed delirium after 
heart surgery with the 
application of heart lung-
machine, admitted into the 
ICU. 
 
70.10 ± 9.30 
 
70.90 ± 9.90 









Adult patients who 
underwent elective coronary 
artery bypass grafting, valve 
replacement or both 
between February 2005 and 
August 2007 admitted into 
the ICU and who failed at 
least one trial of continuous 
positive airway pressure and 
had agitation. 
 
58.91 ± 10.49 
 
61.17 ± 9.15 
ICU = Intensive Care Unit, SD = Standard Deviation. 
 















Atalan et al.114 CAM-ICU + RASS 
sedation score 
Patients received 5milligrams of morphine 
sulphate intramuscularly which was 
repeated every hour until the adequate 
sedation and target RASS scores (between 
-1 and +1) were achieved. 
Patients received 5milligrams of haloperidol 
intramuscularly which was repeated every 
hour until the adequate sedation and target 
RASS scores (between -1 and +1) were 
achieved. 
 
Protocol in both groups 
 
In patients who were still agitated despite the administration of 20milligrams per day of 
morphine sulphate or haloperidol, 2.5milligrams of lorazepam per oral, twice a day was 
added to the treatment regime. All delirious patients were re-evaluated every 12 hours or for 
a maximum of 10 days following surgery. 
Tagarakis et al.71  4-point scale for 
evaluation of 
delirium 
Patients received 8milligrams of 
ondansetron intravenously on detection of 
delirium. 
Patients received 5milligrams of haloperidol 
intravenously on detection of delirium. 
 
Protocol in both groups 
 
All patients were evaluated before and 10 minutes after the injection with a 4-point scale for 
the evaluation of delirium. No further details were provided on the treatment procedure used 
in the study or if any study participants required any additional treatment (either 
pharmacological or non-pharmacological) other than restraints. 
Yapici et al.70  CAM-ICU  
Protocol in both groups 
 
Initially, all patients were commenced on a fentanyl infusion (20-50micrograms/kg/hr) and a 
midazolam infusion (0.05-0.1milligrams/kg/hr) prior to randomisation into the intervention or 
comparator groups.  
Patients received a 0.3-
0.7micrograms/kg/hr of dexmedetomidine 
intravenously. After the initiation of the 
dexmedetomidine treatment, the 
background sedation of fentanyl and 
midazolam were weaned off and ceased. 
The dexmedetomidine dose was titrated 
based on the patients’ heart rate and 
blood pressure response.   
Patients received 0.05-0.2milligrams/kg/hr of 
midazolam intravenously to control delirium. 
Some patients in this group received 
haloperidol 5milligrams intramuscularly 4 times 
per day for treatment of agitation as well as 
other drugs such as benzodiazepines, 
haloperidol or atypical antipsychotics. 
 
  
Protocol in both groups 
Both groups received nonsteroidal anti-inflammatory drugs or paracetamol for analgesia. 






This systematic review examined eleven primary outcomes of interest. Most were not measured or assessed 
in the included clinical trials, as summarised in Table 7  
 





Atalan et al.114 
 
Tagarakis et al.71 
 
Yapici et al.70 
Mortality Y N N 
Total duration of delirium   Y N N 
Severity of the delirium Y N N 
Frequency in the use of physical restraints N Y N 
Quality of life during ICU stay N N N 
Family members satisfaction with delirium management N N N 
Duration and severity of patient aggression or violent episodes 
against healthcare staff, other patients and family members or 
other persons in contact with the patient 
N N N 
The number and severity of patient falls N N N 
The number and severity of patient accidental self-harm events N N N 
Harms related to pharmacological interventions Y Y Y 
Harms related to over-sedation N N N 
Abbreviations: N= not measured, Y = measured and assessed. 
 
Five secondary outcomes of interest were included. Many of those secondary outcomes were not measured 










Atalan et al.114 
 
Tagarakis et al.71 
 
Yapici et al.70 
ICU length of stay Y N N 
Length of hospital stay after ICU discharge   Y N N 
Total hospital length of stay Y N N 
Need for additional medication for delirium management Y N Y 
Use of additional medication for delirium management Y N Y 
Abbreviations: N= not measured, Y = measured and assessed.  
 
All included studies reported different clinical outcomes and were highly heterogeneous therefore a meta-
analysis was unable to be conducted and instead a narrative approach was adopted. The results have been 




Only one study assessed hospital mortality.114 Atalan et al. reported that there was no statistically significant 
difference in hospital mortality between the morphine treatment group and the haloperidol treatment group 
(7.7% [2/26] vs. 3.7% [1/27]; p=0.61).  
 
Total duration of delirium 
Only one study assessed the total duration of delirium.114 Atalan et al. measured the duration of delirium in 
hours, reporting that there was no significant difference between the morphine group compared with the 
haloperidol group. The mean duration was 36.0 +/- 16.1 hours (range 12-90 hours) (33.92 +/- 16.70 vs. 31.56 
+/- 16.6 [p=0.607]).  
 
Severity of the delirium  
While the presence of delirium was assessed in all three studies only one study assessed the severity of 
delirium.114 The screening tools used in these studies to detect the presence of delirium included the 
Richmond Agitation Sedation Scale (RASS), the Confusion Assessment Method for Intensive Care Units 
(CAM-ICU)70, 114 and a 4-point scale.71 RASS is a validated and reliable tool used to assess sedation level. 
This 10-point scale ranges from +4 to -5, where +4 is indicative of signs of agitation, 0 is descriptive of an 
alert and calm patient, and -5 is indicative of a unresponsive and unarousable patient.115 CAM-ICU is a 
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validated and reliable tool used to screen for delirium that can be used for either intubated or extubated 
patients.116 The 4-point scale was developed by Bayindir et al. to detect and evaluate delirium.109 The 4-point 
scale rates as follows: 0-normal, 1-patient with restlessness and mild confusion but cooperative, 2-patient is 
disorientated but cooperative, memory gaps, 3-patient disorientated and uncooperative with augmented 
mobility that could put the patient in danger, 4-patient totally disorientated, violent and aggressive, presence 
of hallucinations.109 
Atalan et al. measured delirium severity using the RASS and reported that there was a reduction in severity 
of the delirium in both the control and intervention groups in conjunction with decreased RASS scores and 
drug dose over a five-day period. The mean daily doses of morphine on Day 1 was 9.81 mg to 0.0 mg on Day 
5 vs haloperidol on Day 1 10.96 mg to 0.28 mg Day 5.114 While Yapici et al. measured and reported the 
presence of delirium using RASS, no explicit statement was provided regarding measurement of the severity 
of the delirium experienced by participants. Tagarakis et al. assessed the presence of delirium with a 4-point 
scale which was used pre and ten minutes after the administration of the treatment drug. There was no explicit 
statement provided by Tagarakis et al. regarding measuring the severity of delirium however they did report 
a statistically significant improvement in the test score after the administration of both ondansetron and 
haloperidol (3.1 +/- 0.4 vs 3.1 +/- 0.4 pre-administration vs 1.2 +/- 0.1 vs 1.3 +/- 0.1 post administration 
[p=<0.01]).  
 
Frequency in the use of physical restraints  
One study reported the use of physical restraints.71 Tagarakis et al. reported that unresolved delirium 
continued in seven participants included in the ondansetron treatment group and six in the haloperidol 
treatment group that required restraints and returned to a calm state.71 However, no additional details were 
reported on how patients were returned to calmness or how long physical restraints were required.  
 
Harms and Adverse Effects 
Assessing the harms of pharmacological interventions in the treatment of delirium after cardiac surgery and 
how harms were reported in the included clinical trials was a primary outcome of interest for this systematic 
review.  
 
Harms related to pharmacological interventions 
The three included studies provided statements related to harms associated with pharmacological 
interventions.70, 71, 114 Atalan et al. monitored harms related to pharmacological interventions by observation, 
reporting that no serious or adverse effects were observed in either the haloperidol or morphine treatment 
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group but provided no additional details.114 Likewise Tagarakis et al. provided a statement that ondansetron 
was safer with milder side effects compared with haloperidol with no additional details. Yapici et al. measured 
and monitored heart rate (HR), blood pressure (BP), respiration rate (RR), peripheral capillary oxygen 
saturation (SpO2), partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2) and arterial 
blood gases (ABGs) and reported that they found significantly different HRs between the dexmedetomidine 
treatment group and the midazolam treatment group but did not observe any haemodynamic side effects. 
Yapici et al. reported that 50% of the patients with hypotension in the dexmedetomidine treatment group 
responded successfully to dose titration or the administration of intravenous fluids.70  
 
A summary of the harms based on the McHarm appraisal tool is provided in Table 9. Only two of the 15 
questions were answered. The primary authors of the included clinical trials were contacted requesting further 





Table 9: Summary of the reporting of harms using McHarm appraisal tool of the included studies 
Harms Question Atalan et al.114 Tagarakis et al.71 Yapici et al.70 
Q1 Were the harms PRE-DEFINED using 
standardised or precise definitions? 
N N N 
Q2 Were SERIOUS events precisely defined? N N N 
Q3 Were SEVERE events precisely defined? N N N 
Q4 Were the number of DEATHS in each study 
group specified OR were the reason(s) for 
not specifying them given? 
Measured and reported 
the number of deaths in 
each study group. 
However, no details were 
provided on the reasons 
for the deaths nor were 
there details on why that 
information was not 
provided. 
N N 
Q5 Was the mode of harms collection specified 
as ACTIVE? 
N N N 
Q6 Was the mode of harms collection specified 
as PASSIVE? 
N N N 
Q7 Did the study specify WHO collected the 
harms? 
N N N 
Q8 Did the study specify the TRAINING or 
BACKGROUND of who ascertained the 
harms? 
N N N 
Q9 Did the study specify the TIMING and 
FREQUENCY of collection of the harms? 
N N Reported that the 
timing and frequency of 
data related to drug 
effectiveness was 
conducted at 0, 6, 12 
and 24-hour time 
points. However, it is 
difficult to ascertain if 
this data collection was 
specific to harms data 
collection. 
Q10 Did the author(s) use STANDARD scale(s) 
or checklist(s) for harms collection? 
N N N 
Q11 Did the author(s) specify if the harms 
reported encompass ALL the events 
collected or a selected SAMPLE? 
N N N 
Q12 Was the NUMBER of participants that 
withdrew or were lost to follow-up specified 
for each study group? 
N N N 
Q13 Was the TOTAL NUMBER of participants 
affected by harms specified for each study 
arm? 
N N N 
Q14 Did the author(s) specify the NUMBER for 
each TYPE of harmful event for each study 
group? 
N N N 
Q15 Did the author(s) specify the type of analysis 
undertaken for harms data? 
N N N 






ICU length of stay 
One study assessed the total ICU length of stay45 in days, reporting that there was no significant difference 
between the morphine group compared with the haloperidol group. The mean duration was 3.3 days vs 2.8 
days (2.85 +/- 1.48 days vs. 3.31 +/- 2.32 [p=0.402]). 
 
Length of hospital stay after ICU discharge  
Atalan et al. reported ICU length of stay and the total hospital length of stay. Although there was no explicit 
statement regarding the length of hospital stay after ICU discharge this can be deduced from both sets of 
data; mean duration of 5.2 days vs 6.1 days in the haloperidol group compared with the morphine group 
respectively. 
 
Total hospital length of stay 
The total length of hospital stay114 in days was assessed in one study, in which it was reported that there was 
no significant difference in the morphine group compared with the haloperidol group. The mean duration was 
8.5 days vs 8.9 days (8.93 +/- 3.11 days vs. 8.54 +/- 3.44 [p=0.607]).  
 
Need for additional medication for delirium management  
This secondary outcome concerned the need for additional (rescue) medication that may have been required 
in addition to the study pharmacological agent. Two studies included in this systematic review reported the 
need for additional medication for delirium management.70, 114 Atalan et al. reported that lorazepam 2.5mg 
(orally twice daily) was administered to patients who had received more than 20mg of the treatment drug and 
remained delirious. Atalan et al. reported that those treated with additional medication to manage unresolved 
delirium required significantly less additive medication in the morphine treatment group compared with the 
haloperidol treatment group (one participant vs eight participants). Yapici et al. reported that the midazolam 
treatment group required the use of additional medications such as benzodiazepines, haloperidol or atypical 
antipsychotics to manage unresolved delirium. Yapici et al. stated that some midazolam treatment group 
participants received 5mg haloperidol intramuscularly four times per day for the treatment of excessive 
agitation. However, no further details were provided. In both studies, there were no explicit statements 
regarding the clinical judgment used to determine the need for additional medication compared with the actual 
administration of additional medication, such as the review process including patient assessment or whether 
non-pharmacological interventions were tried first. 
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Use of additional medication for delirium management 
This secondary outcome concerned the need for additional doses of the pharmacological study agents. Atalan 
et al. reported that patients in both the morphine and haloperidol groups where administered 5mg of the 
treatment drug every hour until adequate sedation and a target RASS score of -1 to +1 was achieved. Yapici 
et al. reported that both the dexmedetomidine and midazolam was titrated to maintain the level of sedation 
within a predefined range of 10% increases or decreases in infusion rate.  
 
In this chapter the underlying systematic review conducted to evaluate the effectiveness and harms of 
pharmacological interventions in the treatment of delirium following cardiac surgery was provided. A detailed 
description of the search results, the study selection process and the assessment of methodological quality 
was presented which was followed by the characteristics of the included studies. Finally, a narrative synthesis 
of the results organised by outcome was provided. In the next chapter, the findings and limitations of the 
systematic review will be discussed, along with the conclusions and the implications for practice and future 




CHAPTER 5: DISCUSSION, CONCLUSIONS AND RECOMMENDATIONS FOR PRACTICE 
AND RESEARCH 
_____________________________________________________________________________________ 
Two objectives are addressed in the final chapter of this thesis. The first objective is to provide an overview 
of the findings of the review, highlighting the effectiveness of pharmacological interventions on delirium after 
cardiac surgery as well as the harms of those pharmacological interventions on cardiac function after cardiac 
surgery. The second objective is to discuss the strengths and limitations of the review before finally concluding 
with remarks regarding implications of this review for clinical practice and future research. 
 
Overview of findings 
Cardiac patients are at increased risk of delirium after cardiac surgery, in which the duration and severity 
adversely impacts morbidity and mortality.117-119 Treating the episode is challenging as there is a lack of 
knowledge about the exact cause.33, 37 The aim of this  systematic review was to identify the effectiveness of 
any pharmacological intervention for the treatment of identified delirium after cardiac surgery in reducing the 
duration and severity of the delirious episode and to assess the harms associated with those medications.99 
Only three trials were identified and included in this review (morphine vs haloperidol, ondansetron vs 
haloperidol and dexmedetomidine vs midazolam).70, 71, 114 Two trials indicated that the pharmacological 
interventions were effective in managing the symptoms of hyperactive delirium after cardiac surgery70, 114 
while the remaining trial suggests that both ondansetron and haloperidol had “good controlling effects”.71 The 
trials were too heterogeneous for a meta-analysis to be performed and therefore a narrative approach was 
taken. 
In all three studies, there were methodological limitations in relation to poor reporting of information related to 
true randomisation, allocation concealment, blinding, follow-up of participants, intention-to-treat and statistical 
analysis procedures and small sample sizes. It was also unclear for all three studies, if the outcomes were 
measured in a reliable and consistent manner as there were no details pertaining to the number of raters, 
training of raters of delirium or the intra and inter-rater reliability within the studies.  
The investigators of the study in which the effectiveness of haloperidol was compared with morphine for the 
treatment of delirium stated that morphine was found to be a reasonable alternative to haloperidol in the 
management of delirium following cardiac surgery due to its rapid action and absence of side effects.114 
However, critical appraisal of the study revealed significant concerns about potential bias and associated drug 
harms that may affect this group of patients. Therefore, the findings of the study do not support the adoption 
of morphine as a treatment alternative for delirium in the postoperative cardiac surgical patient in practice. 
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In the reporting of harms, Atalan et al. did not outline any predefined harms relating to morphine, the 
monitoring of potential harms or how harms would be managed, including the management of over-sedation. 
According to the Food and Drug Association (FDA), the known effects of the opioid antagonist morphine is 
that it suppresses the central nervous system (CNS) and respiratory drive leading to decreased level of 
consciousness and rate of breathing, oxygenation and possibly apnoea. Regular monitoring of sedation and 
delirium was performed in this study, using RASS and CAM-ICU respectively.114 However, details were 
lacking about monitoring respiratory function and over-sedation or how it was to be managed. Additionally, 
morphine may cause vomiting, nausea and constipation which was not acknowledged or reported in this 
study. Mortality rates were reported; however, details were not provided relating to cause of death or follow-
up of participants. 
In this study, morphine was administered intramuscularly (IM) every hour until a RASS sedation score of -1 
to +1 was achieved.114 Morphine is an opioid with excellent analgesic efficacy and euphoric properties, 
commonly indicated for the management of pain.57 Postoperative pain is a known complication after cardiac 
surgery.120, 121 Studies have suggested that postoperative pain is a contributing factor in the development of 
delirium if not managed effectively.120, 121 Opioids, such as morphine are highly effective, inexpensive and can 
be administered via a number of routes with the peak therapeutic effect varying depending on the route of 
administration. However, morphine administered IM has been found to have a slower absorption rate and has 
an unreliable distribution.122-124 Studies have been conducted comparing intravenously (IV) and IM 
administered morphine.122-124 The results revealed that IV administration is superior in terms of a significantly 
faster onset (5 minutes vs 20 minutes) with improved analgesic effect compared with IM administration.122-124 
This study omitted details pertaining to pain assessment and management, therefore it was difficult to 
ascertain if the effect was a result of over-sedation to manage the symptoms of hyperactive delirium or pain 
management as opposed to effectively managing delirium.  
Morphine may be contraindicated due to potential complications of bleeding during critical illness.122, 124, 125 
Morphine is known to cause the release of histamine, which may lead to vasodilation and an increased risk 
of bleeding (particularly for the surgical patient).122, 124, 125 This deleterious effect on a haemodynamically 
unstable postoperative cardiac surgical patient, may result in decreased heart rate, hypotension, decreased 
venous return, respiratory depression, nausea, vomiting, constipation, tolerance and physical dependence.122, 
124, 125 A reduction in opioid use to reduce the risk of over-sedation, delirium and respiratory depression is 
advocated in the newly released guideline for Pain, Agitation and Delirium, by the Society of Critical Care 
Medicine.57   
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The Atalan et al. study report was incomplete with regard to effectiveness and harms; therefore, it was difficult 
to verify if morphine was effective in reducing the severity and duration of the hyperactive delirium or if the 
deliria symptoms were controlled through sedation. It is also difficult to verify if there were any harms as harms 
and adverse effects were not reported fully in this trial and there was no follow-up of participants for side 
effects. Therefore, no conclusions can be made about the findings of this study.  
The investigators of the study in which the effectiveness of haloperidol was compared with ondansetron for 
the treatment of delirium stated that both ondansetron and haloperidol were found to have good controlling 
effects on delirium following cardiac surgery.71 However, critical appraisal of the study revealed significant 
concerns about potential bias and associated drug harms that may affect this group of patients. Therefore, 
the findings of the study do not support the adoption of ondansetron as a treatment alternative for delirium in 
the postoperative cardiac surgical patient in practice. In this study, ondansetron was administered once on 
detection of delirium with screening performed ten minutes following the administration of the medication 
using an unvalidated tool developed by Bayindir et al.71, 109  
Tagarakis et al. did not outline any predefined harms relating to ondansetron, the monitoring of harms or how 
harms would be managed, mortality or follow-up of participants. There was no information about how data 
were measured or who collected it, and therefore no details provided relating to severity, duration, frequency 
of delirium screening, cardiac or electrocardiogram (ECG) monitoring. Furthermore, there were no details 
provided about the management for ongoing delirium other than additional pharmacological agents and 
physical restraints.  
Ondansetron is a 5HT3 serotonin receptor antagonist that may cause confusion, anxiety, agitation, 
depression, restlessness, headaches and insomnia.126, 127 Furthermore, the administration of IV ondansetron 
in patients with a cardiac history although rare, may result in QT prolongation and cardiac arrhythmia.126, 127 
The reporting was incomplete, so it is difficult to verify if ondansetron is effective for reducing the severity and 
duration of delirium and whether it is an appropriate choice for delirium management in the postoperative 
cardiac patient. Therefore, no recommendations can be drawn from the findings of this study. 
The investigators of the remaining study in which the effectiveness of dexmedetomidine was compared with 
midazolam for the treatment of delirium stated that dexmedetomidine may help eliminate the symptoms of 
delirium and reduce mechanical ventilation times with no haemodynamic compromise.70 However, critical 
appraisal of the study revealed significant concerns about potential bias and associated drug harms that may 
affect this group of patients. Therefore, the findings of the study do not support the adoption of 




Reports of hypotension and bradycardia were documented in this study which were not identified as adverse 
effects associated with the pharmacological agent.70 Dexmedetomidine is a highly selective adrenergic alpha-
2 agonist that targets the alpha-2 adrenergic receptors at the pre and postsynaptic terminals producing an 
analgesic, anxiolytic and sedative effect.128 Alpha-2 receptors are located in the CNS and peripheral nervous 
system (PNS), including smooth muscle tissue.128 The responses to activation of the receptors in other areas 
include decreased salivation, secretion and bowel motility in the gastrointestinal tract and contraction of 
vascular and other smooth muscle, causing vasoconstriction.128, 129 The effect of dexmedetomidine on the 
sympathetic nervous system results in hypotension and bradycardia resulting in decreased cardiac output.128-
130 Bradycardia may occur in 43% of cases, hypotension in 53% and hypertension in 28%.130, 131 Yapici et al. 
reported that hypotension and bradycardia occurred in the dexmedetomidine group and that this was 
managed with fluid administration or by reducing the dexmedetomidine infusion rate.  
Yapici et al. stated that “considering the pre-existing cardiac problems of these patients, we did not use bolus 
dosing regimens or administer an initial dose in <10 minutes. Therefore, we did not observe any hemodynamic 
side effects”.70 (p97) However, it was reported that “we found significantly different heart rates between the 
groups at 12- and 24-hour time points, that may be due to inhibited sympathetic activity causing a decrease 
in heart rate”.70 (p97) Also, Yapici et al. briefly reported that hypotension was identified and that it was managed 
with fluid administration or reducing the dexmedetomidine dose rather than treating it as an adverse effect. 
There was no mention of an overt a priori intention to monitor and report harms, therefore it can be concluded 
that these known effects were not identified as drug harms relating to the intervention. 
During the initial postoperative period following cardiac surgery, cardiac function is often variable as a result 
of large fluid shifts and inflammation.60, 61 This may lead to haemodynamic vulnerability and instability.60, 61 
Postoperative cardiac patients are reliant on adequate cardiac output.60, 61 Cardiac output is dependent on 
adequate heart rate and stroke volume.61-63 Low cardiac output may lead to low coronary perfusion and 
therefore impaired cardiac function.61, 63 This in turn may lead to tissue and cerebral hypoperfusion and 
multiorgan dysfunction, increasing the risk of death.60, 61, 63, 132 Careful consideration must be exercised when 
administering dexmedetomidine in this patient cohort. 
All three clinical trials emphasised the benefits of the interventions under investigation with little reference to 
the associated harms. For all three studies harms reporting was limited. As there was a paucity of information 
it is difficult to ascertain if there was an absence of adverse effects or if adverse effects were not measured 
or reported.  
When reporting and analysing harms there are standards that researchers and reviewers should adhere to.104, 
105 These statements have been developed in order to generate balanced results and conclusions that 
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address both benefits and harms of interventions.104, 105 Benefits are often accorded greater prominence when 
reporting results in trials with little effort made to report harms.104, 105 
For RCTs, the CONSORT harms extension, highlights the necessity for clinical trials to report both benefits 
and harms of interventions and provides a 22-item checklist and flow diagram for reporting results.104 The aim 
of this statement is to improve the quality of reporting of drug effectiveness and harms. Originally, there was 
only one checklist item that addressed the reporting of safety. However, in 2003 there was considerable 
evidence suggesting that harms related data reported in RCTs needed improving, with a working group 
established to address the deficit.104 From this, ten new recommendations were added related to reporting 
harms that were then developed into the 22-item checklist. Within this was the recommendation to use the 
term “harm” rather than safety as “safety” may be misused or result in misleading conclusions. “Harms” is 
also preferred as the term encompasses unintended side effects, adverse events, adverse effects and drug 
reactions.104 For systematic reviews and meta-analyses, the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis) statement is available.105 This statement provides an evidence-
based, minimum set of items for harms reporting reviews that evaluate RCTs.105  
A previously conducted systematic review was identified75 from the preliminary search which was similar in 
part to this review. However, there were some significant differences and a number of limitations. Firstly, 
recommendations made by PRISMA, extension for harms reporting in systematic reviews was not 
systematically followed. Mu et al.75 assessd both effectiveness and harms however events considered harmful 
to this patient cohort were not described. The adverse effects were not assessed using a structured tool nor 
critically appraised in a systematic way. Additionally, the search strategy conducted by Mu et al.75 was a 
limited search in five databases for published RCTs with a limited timeframe from 1937 to 2013 with no 
examination of the unpublished or grey literature. Limited details relating to search terms were provided. It 
remains unclear if Mu et al.75 restricted their sample to postoperative cardiac surgical patients treated in the 
ICU. With regards to the comparators, Mu et al.75 noted that “studies with comparisons of pharmacological 
agents for sedation or pain were excluded” 75(p195) which differs to the current systematic review. Overall, Mu 
et al.75 found inconclusive evidence to support the treatment of delirium using pharmacological agents, a 
finding that aligned with the findings of the current review. Additional existing review protocols and completed 
systematic reviews on the effectiveness of pharmacological agents used for the treatment of delirium identified 
from the search focused on prevention rather than treatment and therefore, could not be aligned with this 
review.76-79, 80 The findings from all the excluded studies, except one109 produced similar results. These studies 
were observational studies and therefore excluded from this review as the preference was for experimental 
studies. 3, 111 One cohort study that was identified as a precursor to an included RCT71 found ondansetron to 
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be effective in the treatment of hyperactive delirium after cardiac surgery.109 This finding differed from this 
review’s findings however due to quality concerns, lack of detail in reporting and no reporting related to drug 
harms caution is advised.109 
 
Conclusion 
There is currently insufficient evidence to confirm or refute the effectiveness of morphine compared with 
haloperidol, ondansetron compared with haloperidol or dexmedetomidine compared with midazolam for 
reducing the duration or severity of hyperactive delirium in the postoperative cardiac surgical patient treated 
in the ICU after cardiac surgery. The available evidence indicates there are no clinically significant differences 
in the outcomes measured. Harms reporting was superficial and insufficiently addressed for all three studies. 
This review found the included studies emphasised the effectiveness of the trialed intervention with no 
examination of the known and significant harms that may occur from the administration of these 
pharmacological agents to this patient cohort. 
Strengths and Limitations of the review  
The main strength of the review was that it was conducted systematically according to validated procedures 
using an a priori protocol.99 We also examined the harms reporting of the included studies which although 
important, is seldom reported in reviews of effectiveness. In addition, the search strategy of this review was 
extensive, examining both published, unpublished and grey literature with an unlimited timeframe but limited 
to English language only. The main limitations of this review pertain primarily to a lack in the number of quality 
studies on the treatment of hyperactive delirium identified in patients after cardiac surgery. Another limitation 





Implications for practice 
Summary of Findings (SoF) tables using the GRADE approach to rate the quality of the evidence were created 
and are presented in Tables 10-12. Utilising GRADE provided a transparent and structured process where 
the evidence was rated on the following: absolute risk for the treatment, ranking of the quality of the evidence 
based on the risk of bias, directness, heterogeneity, precision and risk of publication bias.107 The outcomes 
reported in the SoF include: mortality, duration, severity or presence of delirium, harms related to 
pharmacological interventions and were found to be of low quality. There is insufficient evidence to support 
the use of morphine, ondansetron or dexmedetomidine as effective pharmacological agents in treating 
hyperactive delirium. There is insufficient information to inform the development of practice guidelines. Until 
better quality evidence is available, practices relating to the effective management of hyperactive delirium 
after cardiac surgery will continue to be informed by clinical judgment and clinician discretion within local 
current policies and guidelines. It is imperative that clinicians remain vigilant to the known indications, 
contraindications and associated harms of the pharmacological agents that are being administered and to 
understand the implications of such drugs on cardiac performance in the initial postoperative recovery phase 
after cardiac surgery. Therefore, it is vital that the potential harms associated with any pharmacological agent 
are carefully considered in the context of the patient condition and setting 
Implications for research 
Future large-scale, high-quality, multi-center RCTs are required in this area, in which reliable and valid 
outcome measures are consistently applied. Future trials need to accord harms the same attention as 
treatment benefits and follow the recommendations as defined by the CONSORT harms extension. Future 
systematic reviews should also consider following the recommendations for harms reporting as defined by 
the PRISMA extension for harms reporting in systematic reviews. In lieu of high-quality RCTs, future reviews 
could consider the inclusion of high-quality, observational studies. This would provide clinicians with balanced 
reports on both the benefits and harms of drug interventions so that informed decisions can be made based 
on unbiased evidence.  
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Summary of Findings 
Table 10: Morphine vs Haloperidol 
Effectiveness and harms of pharmacological interventions in the treatment of delirium after cardiac surgery 
Bibliography: Leigh V, Stern C, Elliott R, Tufanaru C. Effectiveness and harms of pharmacological interventions in the treatment of 
delirium in adults in intensive care units post cardiac surgery: a systematic review protocol. JBI Database System Rev Implement Rep. 2019; 
(in press) 
Patient or population: Adults, treatment of delirium after cardiac surgery  
Setting: Cardiothoracic Intensive Care Unit 
Intervention: Morphine  
Comparison: Haloperidol  
Outcomes Impact № of 
participants  
(studies)  




assessed with: number of deaths that occurred in each 
study group  
No significant difference in hospital mortality reported 
between groups (p=0.610)  
53 
(1 RCT)  
⨁◯◯◯ 
VERY LOW a,b,,d 
Total duration of delirium 
assessed with: Confusion Assessment Method for Intensive 
Care Unit (CAM-ICU)  
No significant difference in duration of delirium between 
groups (p=0.607) 
53 
(1 RCT)  
⨁◯◯◯ 
VERY LOW a,b,e 
Severity of the delirium 
assessed with: Richmond Agitation Sedation Scale (RASS)  
Severity of delirium was reduced in both groups in 
conjunction with decreased RASS scores, decreased 
drug dose over an increased number of days. No 
statistical data reported.  
53 
(1 RCT)  
⨁◯◯◯ 
VERY LOW a,b,c,e 
Harms related to pharmacological interventions 
Assessed with: observation  
No adverse effects related to the pharmacological 
interventions were observed with no further details 
provided. No statistical data was reported. 
53 




*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).  
CI: Confidence interval  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Concerns related to true randomisation, performance bias and allocation concealment  
b. Concerns with small sample size. Sample size calculations to establish statistical power not reported  
c. Confidence intervals, odds ratio, absolute risk or relative risks were not provided 
d. Concerns related to Intention-to-Treat (ITT), no follow-up, attrition bias, missing outcome data  
e. Concerns related to reliability and validity. No reporting on the number of raters, training of the raters, the intra-rater reliability or the inter-rater reliability within 
the study 




Table 11: Ondansetron vs Haloperidol 
Effectiveness and harms of pharmacological interventions in the treatment of delirium after cardiac surgery 
Bibliography: Leigh V, Stern C, Elliott R, Tufanaru C. Effectiveness and harms of pharmacological interventions in the treatment of 
delirium in adults in intensive care units post cardiac surgery: a systematic review protocol. JBI Database System Rev Implement Rep. 2019; 
(in press) 
Patient or population: Adults, treatment of delirium after cardiac surgery 
Setting: Cardiothoracic Intensive Care Unit  
Intervention: Ondansetron  
Comparison: Haloperidol  






Severity of delirium 
assessed with: 4-point scale developed by Bayinder et al. 2000  
Statistically significant improvement in test score rating 
after administration of both ondansetron and 
haloperidol (p=0.01) but no significant difference 
between the intervention and the comparator (no 
statistical data reported).  
80 




Frequency in the use of physical restraints 
assessed with: number of patients requiring physical restraints  
Use of restraints reported in both groups. Ondansetron 
(n=7) vs haloperidol (n=6)  
80 
(1 RCT)  
⨁◯◯◯ 
VERY LOW ,b,c 
Harms related to pharmacological interventions  Reported that ondansetron was safer with milder side 
effects compared with haloperidol.  No reporting on 
what side effects or adverse effects were noted in 
either groups. No statistical data reported. No further 
details were provided. 
80 




*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).  
CI: Confidence interval  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Concerns related to true randomisation, performance bias and allocation concealment  
b. Concerns with small sample size. Sample size calculations to establish statistical power not reported 
c. Confidence intervals, odds ratio, absolute risk or relative risks were not provided 
d. Concerns related to Intention-to-Treat (ITT), no follow-up, attrition bias, missing outcome data  
e. Concerns related to reliability and validity. No reporting on the number of raters, training of the raters, the intra-rater reliability or the inter-rater reliability within 
the study 





Table 12: Dexmedetomidine vs Midazolam 
Effectiveness and harms of pharmacological interventions in the treatment of delirium after cardiac surgery 
Bibliography: Leigh V, Stern C, Elliott R, Tufanaru C. Effectiveness and harms of pharmacological interventions in the treatment of 
delirium in adults in intensive care units post cardiac surgery: a systematic review protocol. JBI Database System Rev Implement Rep. 2019; 
(in press) 
Patient or population: Adults, treatment of delirium after cardiac surgery  
Setting: Cardiothoracic Intensive Care Unit  
Intervention: Dexmedetomidine  
Comparison: Midazolam  






Severity of the delirium 
assessed with: RASS  
Reported that dexmedetomidine showed a statistically 
significant difference in RASS scores at 48 and 60 
hours (p=0.0003 and p=<0.0001, respectively).  
71 




Harms related to pharmacological interventions  Reported that dexmedetomidine showed a statistically 
significant difference in heart rates between the groups 
at 12 and 24 hours (p=0.0017 and p=<0.0001, 
respectively). Hypotension was reported with no data 
provided.  
71 




*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).  
CI: Confidence interval  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Concerns related to true randomisation, performance bias and allocation concealment  
b. Concerns with small sample size. Sample size calculations to establish statistical power not reported. 
c. Confidence intervals, odds ratio, absolute risk or relative risks were not provided 
d. Concerns related to Intention-to-Treat (ITT), no follow-up, attrition bias, missing outcome data  
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Appendix I: Search strategy 
NCBI PubMed. Last search conducted on 18 November 2018.  
Search  Query Records 
retrieved 
#1 Delirium[mh] OR delirium*[tw] OR delirious[tw] OR confusion[mh] OR 
confusion[tw] OR confused state*[tw] OR ICU syndrome[tw] OR intensive 
care syndrome[tw] OR psychoses[tw] OR psychosis[tw] OR emergence 
agitation[tw] OR postanesthetic excitement[tw]  
94693 
#2 Cardiac surgical procedures[mh] OR cardiac surgical procedure*[tw] OR 
heart[mh] OR heart surg*[tw] OR cardiac surgery[mh] OR cardiac surg*[tw] 
OR cardiovascular surg*[tw] OR coronary artery bypass[tw] OR cardiac 
artery bypass[tw] OR aortic valve rep*[tw] OR CABG[tw] OR AVR[tw] OR 
mitral valve rep*[tw] OR MVR[tw] OR heart valve surg*[tw] OR transcatheter 
aortic valve implantation [tw] OR TAVI[tw] 
680788 
#3 Postoperative period[mh] OR postoperative period*[tw] OR post operative 
period[tw] OR postop[tw] OR cardiac care[tw] OR intensive care unit[mh] 
OR intensive care[tw] OR ICU[tw] OR critical care[tw] OR critically ill[tw] OR 
coronary care[tw] 
303777 
#4 Pharmacology[mh] OR pharmacol*[tw] OR pharmacology[sh] OR 
medication therapy management[mh] OR drug therapy[mh] OR drug 
therap*[tw] OR drug management[tw] OR drug treatment[tw] OR adrenergic 
alpha-2 [tw] OR dexmedetomidine[tw] OR precedex[tw] OR imidazolines[tw] 
OR imidazolines[mh] OR imidazoline*[tw] OR clonidine[tw] OR 
benzodiazepinones[mh] OR benzodiazepines[tw] OR midazolam[tw] OR 
diazepam[tw] OR valium[tw] OR haloperidol[tw] OR serenace[tw] OR 
seroquel[tw] OR central nervous system depressants[mh] OR hypnotics and 
sedatives[tw] OR central nervous system depressants[tw] OR CNS 
depressant*[tw] OR propofol[tw] OR sedat*[tw] OR antipsychotics[mh] OR 




anticholesteremic agents[mh] OR statin*[tw] OR ondansetron[tw] 
#5 #1 AND #2 AND #3 AND #4 236 
No limitations on date. Language limited to English 
 
 
EBSCO CINAHL. Last search conducted on 18 November 2018. 
Search  Query Records 
retrieved 
#1 TX Delirium OR TX delirious OR TX “confused state” OR TX agitation OR 
TX confusion OR TX ICU syndrome OR TX intensive care syndrome OR TX 
ICU psychosis OR TX intensive care psychosis OR TX psychosis OR TX 
psychoses OR TX psychos* OR TX emergence agitation OR TX 
postanesthetic excitement 
550057 
#2 TX Cardiac surgical procedures OR MH "Heart Valve Diseases+/SU" OR 
MH heart surgery OR TX heart surg* OR MH cardiac surgery OR TX cardiac 
surg* OR TX cardiovascular surgery OR TX coronary artery bypass OR TX 
cardiac artery bypass OR TX aortic valve rep* OR TX CABG OR TX AVR 
OR TX mitral valve rep* OR TX MVR OR TX heart valve surg* OR TX 
transcatheter aortic valve implantation OR TX TAVI 
165986 
#3 MH Postoperative period OR TX postoperative period OR TX post operative 
period OR TX postoperative period* OR TX postop* OR TX cardiac care OR 
MH intensive care OR TX intensive care OR TX ICU OR TX critical care OR 
TX critically ill OR TX coronary care 
620035 
#4 TX Pharmacology OR TX pharma* OR TX medication therapy management 
OR TX drug therapy OR TX drug therap* OR TX drug management OR TX 
drug treatment OR TX adrenergic alpha-2 OR TX dexmedetomidine OR TX 
precedex OR TX imidazolines OR TX imidazoli* OR TX clonidine OR TX 
benzodiazepines OR TX benzodiaz* OR TX midazolam OR TX midaz* OR 
TX diazepam OR TX diaz* OR TX valium OR TX haloperidol OR TX 




TX hypnotics and sedat*OR TX propofol OR TX sedat* OR TX 
antipsychotics OR TX antipsych* OR TX quetiapine OR TX 
anticholesteremic agents OR TX hydroxmethylglutaryl-CoA Reductase 
inhibitors OR TX statin* OR TX ondansetron OR TX zofran  
954#5 #1 AND #2 AND #3 AND #4 4497 
No limitations on date. Language limited to English 
 
Elsevier Embase. Last search conducted on 18 November 2018. 
Search  Query Records 
retrieved 
#1 Delirium:ti,ab OR delirum*/de OR delirious:ti,ab OR confusion:ti,ab OR 
confusion/de OR “confused state”:ti,ab OR “cognitive defect*”/de OR 
“postoperative cognitive dysfunction”:ti,ab OR agitation:ti,ab OR “ICU 
syndrome”:ti,ab OR “intensive care syndrome”:ti,ab OR “ICU psychosis”/de 
OR “ICU psychosis”:ti,ab OR “intensive care psychosis”:ti,ab OR 
psychosis:ti,ab OR psychoses:ti,ab OR psychos*:ti,ab OR “emergence 
agitation”:ti,ab OR “postanesthetic excitement”:ti,ab  
432612 
#2 “heart surg*”:ti,ab OR “cardiac surg*”:ti,ab OR “cardiovascular surgery”/de 
OR “cardiovascular surg*”/de OR “coronary artery bypass”:ti,ab OR “cardiac 
artery bypass”:ti,ab OR “aortic valve rep*”:ti,ab OR CABG:ti,ab OR 
AVR:ti,ab OR “mitral valve rep*”:ti,ab OR MVR:ti,ab OR “heart valve 
surg*”:ti,ab OR “transcatheter aortic valve implantation”:ti,ab OR TAVI:ti,ab 
263549 
#3 “Postoperative period”/de OR “postoperative period”:ti,ab OR “post 
operative period”:ti,ab OR “postoperative period*”:ti,ab OR postop*:ti,ab OR 
“cardiac care”:ti,ab OR “intensive care unit”/de OR “intensive care”:ti,ab OR 
ICU:ti,ab OR “critical care”:ti,ab OR “critically ill”:ti,ab OR “coronary 
care”:ti,ab 
1018324 
#4 Pharmacology/de OR pharmacol*:ti,ab OR “medication therapy 
management”/de OR “drug therapy”/de OR “drug therap*”:ti,ab OR “drug 




OR dexmedetomidine:ti,ab OR precedex:ti,ab OR imidazolines:ti,ab OR 
imidazolines/de OR imidazolines:ti,ab OR imidazoline*:ti,ab OR 
clonidine:ti,ab OR “benzodiazepine derivative”/de OR benzodiazepines:ti,ab 
OR midazolam:ti,ab OR diazepam:ti,ab OR valium:ti,ab OR haloperidol:ti,ab 
OR serenace:ti,ab OR seroquel:ti,ab OR “central nervous system 
depressants”/de OR “central nervous system depressants”:ti,ab OR 
“hypnotics and sedatives”/de OR “hypnotics and sedatives”:ti,ab OR 
propofol:ti,ab OR sedat*:ti,ab OR antipsychotics/de OR antipsychotics:ti,ab 
OR antipsych*:ti,ab OR quetiapine:ti,ab OR “anticholesteremic agents”/de 
OR “anticholesteremic agents”:ti,ab OR statin*:ti,ab OR ondansetron:ti,ab 
#5 #1 AND #2 AND #3 AND #4 380 
No limitations on date. Language limited to English 
 
Wiley Online Library Cochrane Central Register of Controlled Trials. Last search conducted on 18 
November 2018. 
Search  Query Records 
retrieved 
#1 Delirium OR delirium* OR delirious OR confusion OR confused state* OR 
ICU syndrome OR intensive care syndrome OR ICU psychosis OR intensive 
care psychosis OR psychoses OR psychos* OR emergence agitation OR 
postanesthetic excitement  
27987 
#2 Cardiac surgical procedures OR cardiac surgical procedure* OR heart 
surgery OR heart surg* OR cardiac surgery OR cardiac surg* OR 
cardiovascular surgery OR coronary artery bypass OR cardiac artery 
bypass OR aortic valve rep* OR CABG OR AVR OR mitral valve rep* OR 
MVR OR heart valve surg* OR transcatheter aortic valve implantation OR 
TAVI 
38969 
#3 Postoperative period OR post operative period OR postoperative period* 
OR postop* OR cardiac care OR intensive care unit OR intensive care OR 




#4 Pharmacology OR pharma* OR pharmacol* OR medication therapy 
management OR drug therapy OR drug therap* OR drug management OR 
drug treatment OR adrenergic alpha-2 OR dexmedetomidine OR precedex 
OR imidazolines OR imidazolines OR imidazoline* OR clonidine OR 
benzodiazepinones OR benzodiazepines OR midazolam OR diazepam OR 
valium OR haloperidol OR serenace OR seroquel OR central nervous 
system depressants OR hypnotics and sedatives OR propofol OR sedat* 
OR antipsychotics OR antipsych* OR quetiapine OR anticholesteremic 
agents OR statin* OR ondansetron  
504619 
#5 #1 AND #2 AND #3 AND #4 1101 
No limitations on date. Language limited to English 
 
Elsevier Scopus. Last search conducted on 18 November 2018. 
Search  Query Records 
retrieved 
#1 Delirium OR delirium* OR delirious OR confusion OR “confused state*” OR 
ICU syndrome OR “intensive care syndrome” OR ICU psychosis OR 
“intensive care psychosis” OR psychoses OR psychos* OR “emergence 
agitation” OR “postanesthetic excitement”  
22064 
#2 “Cardiac surgical procedures” OR “cardiac surgical procedure*” OR “heart 
surgery” OR “heart surg*” OR “cardiac surgery” OR “cardiac surg*” OR 
“cardiovascular surgery” OR “Cardiac surgical procedures” OR “cardiac 
surgical procedure*” OR “heart surgery” OR “heart surg*” OR “cardiac 
surgery” OR “cardiac surg*” OR “cardiovascular surgery” 
594353 
#3 “Postoperative period” OR “post operative period” OR “postoperative 
period*” OR postop* OR “cardiac care” OR “intensive care unit” OR 





#4 Pharmacology OR pharma* OR pharmacol* OR “medication therapy 
management” OR “drug therapy” OR “drug therap*” OR “drug management” 
OR “drug treatment” OR “adrenergic alpha-2” OR dexmedetomidine OR 
precedex OR imidazolines OR imidazoline* OR clonidine OR 
benzodiazepinones OR benzodiazepines OR midazolam OR diazepam OR 
valium OR haloperidol OR serenace OR seroquel OR “central nervous 
system depressants” OR “hypnotics and sedatives” OR propofol OR sedat* 
OR antipsychotics OR antipsych* OR quetiapine OR “anticholesteremic 
agents” OR statin* OR ondansetron 
7999559 
#5 #1 AND #2 AND #3 AND #4 1705 
No limitations on date. Language limited to English 
 
Clarivate Analytics Web of Science. Last search conducted on 18 November 2018. 
Search  Query Records 
retrieved 
#1 Delirium OR delirium* OR delirious OR confusion OR “confused state*” OR 
ICU syndrome OR “intensive care syndrome” OR ICU psychosis OR 
“intensive care psychosis” OR psychoses OR psychos* OR “emergence 
agitation” OR “postanesthetic excitement”  
243209 
#2 “Cardiac surgical procedures” OR “cardiac surgical procedure*” OR “heart 
surgery” OR “heart surg*” OR “cardiac surgery” OR “cardiac surg*” OR 
“cardiovascular surgery” OR “Cardiac surgical procedures” OR “cardiac 
surgical procedure*” OR “heart surgery” OR “heart surg*” OR “cardiac 
surgery” OR “cardiac surg*” OR “cardiovascular surgery” 
68144 
#3 “Postoperative period” OR “post operative period” OR “postoperative 
period*” OR postop* OR “cardiac care” OR “intensive care unit” OR 
“intensive care” OR ICU OR “critical care” OR “critically ill” OR “coronary 
care” 
574681 
#4 Pharmacology OR pharma* OR pharmacol* OR “medication therapy 




OR “drug treatment” OR “adrenergic alpha-2” OR dexmedetomidine OR 
precedex OR imidazolines OR imidazoline* OR clonidine OR 
benzodiazepinones OR benzodiazepines OR midazolam OR diazepam OR 
valium OR haloperidol OR serenace OR seroquel OR “central nervous 
system depressants” OR “hypnotics and sedatives” OR propofol OR sedat* 
OR antipsychotics OR antipsych* OR quetiapine OR “anticholesteremic 
agents” OR statin* OR ondansetron  
#5 #1 AND #2 AND #3 AND #4 342 
No limitations on date. Language limited to English 
 
Epistemonikos Foundation EPISTEMOIKOS. Last search conducted on 18 November 2018. 
Search  Query Records 
retrieved 
#1 Delirium OR delirium* OR delirious OR confusion OR “confused state*” OR 
ICU syndrome OR “intensive care syndrome” OR ICU psychosis OR 
“intensive care psychosis” OR psychoses OR psychos* OR “emergence 
agitation” OR “postanesthetic excitement”  
10 
#2 “Cardiac surgical procedures” OR “cardiac surgical procedure*” OR “heart 
surgery” OR “heart surg*” OR “cardiac surgery” OR “cardiac surg*” OR 
“cardiovascular surgery” OR “Cardiac surgical procedures” OR “cardiac 
surgical procedure*” OR “heart surgery” OR “heart surg*” OR “cardiac 
surgery” OR “cardiac surg*” OR “cardiovascular surgery” 
1089 
#3 “Postoperative period” OR “post operative period” OR “postoperative 
period*” OR postop* OR “cardiac care” OR “intensive care unit” OR 
“intensive care” OR ICU OR “critical care” OR “critically ill” OR “coronary 
care” 
450 
#4 Pharmacology OR pharma* OR pharmacol* OR “medication therapy 
management” OR “drug therapy” OR “drug therap*” OR “drug management” 
OR “drug treatment” OR “adrenergic alpha-2” OR dexmedetomidine OR 




benzodiazepinones OR benzodiazepines OR midazolam OR diazepam OR 
valium OR haloperidol OR serenace OR seroquel OR “central nervous 
system depressants” OR “hypnotics and sedatives” OR propofol OR sedat* 
OR antipsychotics OR antipsych* OR quetiapine OR “anticholesteremic 
agents” OR statin* OR ondansetron  
#5 #1 AND #2 AND #3 AND #4 23 
No limitations on date. Language limited to English 
 
A hand search for primary studies published in relevant journals (2012 - 2018) 
Australian Critical Care 
Last search conducted on 08 September 2018. 
Search Strategy Records Retrieved 
delirium AND postoperative 107 
Limitations: 2012 to 2018 
 
Journal of Cardiothoracic Surgery 
Last search conducted on 08 September 2018. 
Search Strategy Records Retrieved 
delirium AND postoperative AND cardiac surgery 433 





American Journal of Respiratory and Critical Care Medicine 
Last search conducted on 08 September 2018. 
Search Strategy Records Retrieved 
delirium AND postoperative AND cardiac surgery 34 
Limitations: 2012 to 2018 
 
Intensive Care Medicine 
Last search conducted on 08 September 2018. 
Search Strategy Records Retrieved 
delirium AND postoperative AND cardiac surgery 10 
Limitations: 2012 to 2018 
 
Critical Care Medicine 
Last search conducted on 08 September 2018. 
Search Strategy Records Retrieved 
delirium AND postoperative AND cardiac surgery 4 
Limitations: 2012 to 2018 
 
The search for unpublished studies in relevant websites  
Australian New Zealand Clinical Trials Registry 
Last search conducted on 08 September 2018. 
Query Search Records Retrieved 
#1 Delirium OR delirium* OR delirious OR confusion  182 





Last search conducted on 08 September 2018. 
Query Search Records 
Retrieved 
#1 Delirium OR delirium* OR delirious OR confusion OR “confused state*” 
OR ICU syndrome OR “intensive care syndrome” OR ICU psychosis OR 
“intensive care psychosis” OR psychoses OR psychos* OR “emergence 
agitation” OR “postanesthetic excitement” 
22170 
#2 “Cardiac surgical procedures” OR “cardiac surgical procedure*” OR 
“heart surgery” OR “heart surg*” OR “cardiac surgery” OR “cardiac surg*” 
OR “cardiovascular surgery” OR “Cardiac surgical procedures” OR 
“cardiac surgical procedure*” OR “heart surgery” OR “heart surg*” OR 
“cardiac surgery” OR “cardiac surg*” OR “cardiovascular surgery” 
2867 
#3 #1 AND #2 160 
No limitations on date. Language limited to English 
 
Clinical Trials in New Zealand 
Last search conducted on 08 September 2018. 
Query Search Records 
Retrieved 
#1 Delirium OR delirium* OR delirious OR confusion OR “confused state*” 
OR ICU syndrome OR “intensive care syndrome” OR ICU psychosis OR 
“intensive care psychosis” OR psychoses OR psychos* OR “emergence 
agitation” OR “postanesthetic excitement” 
260 
#2 “Cardiac surgical procedures” OR “cardiac surgical procedure*” OR 
“heart surgery” OR “heart surg*” OR “cardiac surgery” OR “cardiac surg*” 
OR “cardiovascular surgery” OR “Cardiac surgical procedures” OR 




“cardiac surgery” OR “cardiac surg*” OR “cardiovascular surgery” 
No limitations on date. Language limited to English 
 
ProQuest Dissertation and Theses  
Last search conducted on 08 September 2018. 
Query Search Records 
Retrieved 
#1 Delirium OR delirium* OR delirious OR confusion OR “confused state*” 
OR ICU syndrome OR “intensive care syndrome” OR ICU psychosis 
OR “intensive care psychosis” OR psychoses OR psychos* OR 






Appendix II: Studies excluded on full text 
 
Al Tmimi L, Van de Velde M, Herijgers P, Meyns B, Meyfroidt G, Milisen K, et al. Xenon for the prevention of 
postoperative delirium in cardiac surgery: study protocol for a randomized controlled clinical trial. Trials 
2015;16(449):2-9.  
Reason for exclusion: Ineligible intervention. This is a study protocol for a randomized controlled trial (RCT) 
related to intraoperative use of xenon for the prevention of delirium.  
 
Allen J, Alexander E. Prevention, recognition, and management of delirium in the intensive care unit. AACN 
Adv Crit Care 2012;23(1):5-11. 
Reason for exclusion: Not original research. Ineligible population. This is a review paper that identifies the 
risks of using haloperidol. Not a primary study. Not postoperative cardiac surgical patients. 
 
Al-Qadheeb N, Skrobik Y, Schumaker G, Pacheco M, Roberts R, Ruthazer R, et al. Preventing ICU 
subsyndromal delirium conversion to delirium with low-dose iv haloperidol: a double-blind, placebo-
controlled pilot study. Crit Care Med 2016;44(3):583-91. 
Reason for exclusion: Ineligible population. Pilot study re: haloperidol use preventing subsydromal delirium 
in critically ill patients. Exempt population: post cardiac surgical patients. 
 
American Association of Critical Care Nurses (AACN). Delirium Assessment and Management. [Internet]. 
2012 [cited 2017 December 12]. Available from http://ccn.aacnjournals.org/content/32/1/79.full 
Reason for exclusion: Not original research. This is a practice guideline written by the AACN on delirium 
management. Not related to pharmacological treatment of postop cardiac delirium. Not a primary study.  
 
Andrade RGA. The role of ketamine in preventing cognitive dysfunctions in postoperative period of cardiac 
surgery. [Internet]. NCT02782429. 2016. [cited 2017 December 12]. Available from 
https://clinicaltrials.gov/ct2/show/NCT02782429 
Reason for exclusion: Ineligible intervention. This clinical trial is a prevention trial. Currently in progress. No 





Andrejaitiene J. Delirium after cardiac surgery in early postoperative period: Clinical outcome. Intensive 
Care Med 2011;37:S62. 
Reason for exclusion: Not original research. This is a supplementary paper on delirium as a postop 
complication in cardiac patients. Not related to the treatment of delirium.  
 
Anger KE, Szumita PM, Baroletti SA, Labreche MJ, Fanikos J. Evaluation of dexmedetomidine versus 
propofol-based sedation therapy in mechanically ventilated cardiac surgery patients at a tertiary academic 
medical center. Crit Pathw Cardiol 2010;9(4):221-6. 
Reason for exclusion: Ineligible intervention. Prospective study involving the use of dexmedetomidine vs 
propofol for sedation of cardiac surgical patients. Not related to the treatment of delirium.  
 
Arora RC, Djaiani G, Rudolph JL. Prediction, prevention and management of delirium in the critically ill 
cardiac patient. [Internet]. NCT02206880. 2014. [cited 2017 December 12]. Available from 
https://clinicaltrials.gov/ct2/show/NCT02206880 
Reason for exclusion: Ineligible intervention. This is a clinical trial based on prediction and incidence of 
delirium in the postop cardiac patient. Not related to the pharmacological treatment of postop cardiac 
surgery delirium. Report paper is available. 
 
Arumugam S, El-Menyar A, Al-Hassani A, Strandvik G, Asim M, Mekkodithal A, et al. Delirium in the 
intensive care unit. J Emerg Trauma Shock 2017;10(1):37–46. 
Reason for exclusion: Not original research. Review paper related to delirium in the intensive care unit (ICU) 
patient. 
 
Asghar A, Siddiqui KM, Ahsan K, Chughtai S. Postoperative delirium after cardiac surgery; Incidence, 
management and prevention. Anaesth Pain Intens Care 2017;21(1):109-11.  
Reason for exclusion: Not original research. Special review paper related to delirium in the postop cardiac 





Azeem TMA, Yosif NE, Alansary AM, Esmat IM, Mohamed AK. Dexmedetomidine vs morphine and 
midazolam in the prevention and treatment of delirium after adult cardiac surgery; a randomized, double-
blinded clinical trial. Saudi J Anaesth. 2018;12(2):190-197 
Reason for exclusion: Ineligible intervention. This randomized controlled trial looks at the use of 
dexmedetomidine to prevent delirium in postop cardiac patients. Not related to pharmacological treatment of 
postop cardiac delirium. 
 
Baroncelli F, Barile L, D’Agrosa L, Jain A, Lombrano MR, Marini E, Forfori F, Martinelli G, Meraglia A. 
Adherence to the local guidelines for the management of delirium in a cardiothoracic intensive care unit: a 
clinical audit. Appl Cardiopulm Pathophysiol 2014;18(P39):102-103 
Reason for exclusion: Ineligible outcome. Observational study re: study of compliance to nursing staff 
monitoring and managing delirium as per APA guideline. Not related to treatment of delirium.  
 
Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM, 
Coursin DB, Herr DL, Tung A, Robinson BRH, Fontaine DK, Ramsay MA, Riker RR, Sessler CN, Pun B, 
Skrobik Y, Jaeschke R. Clinical practice guidelines for the management of pain, agitation, and delirium in 
adult patients in the intensive care unit. Crit Care Med 2013;41(1):263-306. 
Reason for exclusion: Not original research. Practice guideline re: delirium management. Not related to 
pharmacological treatment of postop cardiac delirium. Not a primary study.  
 
Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in 
patients with coronary artery disease. Cochrane Database of Systematic Reviews [Internet]. 2011;(9) [cited 
2018 November 18] Available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008012.pub3/abstract 
Reason for exclusion: Not original research. Systematic review re: depression and cardiovascular disease.  
 
Bayindir O, Akpinar B, Can E, Guden M, Sonmez B, Demiroglu C. Ondansetron hydrochloride for the 
treatment of delirium after coronary artery surgery. Cardiothorac Vasc Anesth. 2000;14. 
Reason for exclusion: Higher level study design located. This is a prospective cohort study on the use of 





Bily B, Artemiou P, Sabol F, Bilecova-Rabajdova M, Kolarcik P, Torok P. The role of dexmedetomidine in 
the prevention of postoperative delirium in cardiac surgery patients. Cardiology Letters 2015; 24(6):435-44. 
Reason for exclusion: Ineligible intervention. This is an observational prevention study that looks at the use 
of dexmedetomidine to prevent delirium in postop cardiac patients. Not related to pharmacological treatment 
of postop cardiac delirium. 
 
Bledowski J, Trutia A. A review of pharmacologic management and prevention strategies for delirium in the 
intensive care unit.  Psychosomatics 2012;53(3):203-11. 
Reason for exclusion: Not original research. Ineligible population. A systematic review on the management 
of delirium in the ICU. Not inclusive of cardiac surgical patients admitted into the ICU.  
 
Bokesch PM. A phase III, randomized, double-blind, placebo-controlled, two-arm parallel, multicenter study 
evaluating the efficacy and safety of dexmedetomidine in the prevention of postoperative delirium in 
subjects with CBP. [Internet]. NCT00464763. 2007. [cited 2017 December 12]. Available from 
https://clinicaltrials.gov/ct2/show/NCT00464763 
Reason for exclusion: Ineligible intervention. This clinical trial is a prevention trial. Withdrawn due to the 
incidence of post-operative delirium observed from interim blinded data in DEX-06-09 was significantly 
lower than the current literature in this population.  
 
Breu A, Stransky M, Metterlein T, Werner T, Trabold B. Subsyndromal delirium after cardiac surgery. Scand 
Cardiovasc J 2015;49(4):207-12.  
Reason for exclusion: Ineligible population. Prospective study looking at the incidence of subsydromal 
delirium after cardiac surgery. Not related to treatment of hyperactive delirium.  
 
Brooks P, Spillane JJ, Dick K, Stuart-Shor E. Developing a strategy to identify and treat older patients with 
postoperative delirium. AORN J 2014;99(2):256-76. 
Reason for exclusion: Ineligible population. This is an improvement project. Not related to postop cardiac 
patients. Not related to pharmacological intervention for the treatment of postop delirium.  
 
Brown KE, Mirrakhimov AE, Yeddula K, Kwatra MM. Propofol and the risk of delirium: Exploring the 
anticholinergic properties of propofol. Med Hypotheses 2013;81(4):536-9. 
Reason for exclusion: Not original research. Review paper on the risk of using propofol with the 




Brown CH. Delirium in the cardiac surgical ICU. Curr Opin Anaesthesiol 2014;27(2):117-22. 
Reason for exclusion: Not original research. This is a review paper on delirium in the cardiac surgical ICU. 
Not a primary study.  
 
Brown CH, Neufeld KJ, Needham DM. Delirium, steroids, and cardiac surgery. Anaesth Analg 
2014;119(5):1011-3.  
Reason for exclusion: Not original research. Not a primary study. This is an expert review paper. Not related 
to pharmacological intervention for the treatment of postop delirium. 
 
Brown, CH. An intervention to reduce delirium after cardiac surgery [Internet]. NCT02587039; 2014 [cited 
2017 December 12]. Available from 
https://clinicaltrials.gov/ct2/results?cond=An+intervention+to+reduce+delirium+after+cardiac+surgery.+NCT
02587039.  
Reason for exclusion: Ineligible intervention. This clinical trial is a prevention trial involving ischemic 
preconditioning whereby exposing the patient to brief ischemic periods to prevent development of delirium.  
Not related to the pharmacological treatment of postop cardiac surgery delirium. 
 
Brown CHt, Laflam A, Max L, Lymar D, Neufeld KJ, Tian J, Shah AS, Whitman GJ, Hogue CW. The impact 
of delirium after cardiac surgical procedures on postoperative resource use. Ann Thorac Surg. 
2016;101(5):1663-9. 
Reason for exclusion: Ineligible intervention. Prospective observational study on the effect of delirium on 
length of stay and cost. Not related to the pharmacological treatment of postop cardiac surgery delirium. 
 
Bruder NJ, Velly L. Pharmacologic approach for delirium after cardiac surgery: There is no magic bullet. Crit 
Care Med 2015;43(1):256-7. 
Reason for exclusion: Not original research. Interest paper. Not a primary study.  
 
Cheng H, Li ZM, Young N, Boyd D, Atkins Z, Ji FH, Liu H. The effect of dexmedetomidine on outcomes of 
cardiac surgery in elderly patients. J Cardiothorac Vasc Anesth 2016;30(6):1502-8. 
Reason for exclusion: Ineligible intervention. Retrospective study on the use of demedetomidine vs placebo 




Chorney SR, Gooch ME, Oberdier MT, Keating D, Stahl RF. The safety and efficacy of dexmedetomidine 
for postoperative sedation in the cardiac surgery intensive care unit. HSR Proc Intensive Care Cardiovasc 
Anesth 2013;5(1):17-24. 
Reason for exclusion: Ineligible intervention. Retrospective study on the use of dexmedetomidine on early 
extubation post cardiac surgery. Not related to treatment of postoperative delirium. 
 
Clarke SP, McRae ME, Del Signore S, Schubert M, Styra R. Delirium in older cardiac surgery patients: 
directions for practice. J Gerontol Nurs 2010;36(11):34-45. 
Reason for exclusion: Not original research. Practice guideline on risk factors, prevention and treatment of 
delirium. Not a primary study.  
 
Cooke SE, Dasta J, Fish D, Hassan E, Horst HM, Kelly K, Kaiser K, Jackson CE, Rudis M, Schoenberger 
C, Schoonover L, Takaniski G, Teres D, Thompson K. Clinical practice guidelines for the sustained use of 
sedatives and analgesics in the critically ill adult. Am J Health Syst Pharm 2002;59(2):150-78. 
Reason for exclusion: Not original research. This is a clinical practice guideline on the management of pain 
and sedation in the critically ill. Not related to the treatment of post cardiac surgery delirium.  
 
Cottrell JE, Hartung J. Developmental disability in the young and postoperative cognitive dysfunction in the 
elderly after anesthesia and surgery: do data justify changing clinical practice? Mt Sinai J Med 
2012;79(1):75-94. 
Reason for exclusion: Not original research. Interest paper on the effects of anesthetic on a young and old 
brain. Not related to the treatment of post cardiac surgery delirium. 
 
Crippen D. Life-threatening brain failure and agitation in the intensive care unit. Crit Care. 2000;4(2):81-90. 
Reason for exclusion: Not original research. Interest paper on the effects of alcohol and delirium on the ICU 
patient. Not related to the treatment of post cardiac surgery delirium. 
 
Cropsey C, Kennedy J, Han J, Pandharipande P. Cognitive dysfunction, delirium, and stroke in cardiac 
surgery patients. Semin Cardiothorac Vasc Anesth. 2015;19(4):309-17. 





Crowley K, Urben L, Hacobian G, Geiger K. Valproic acid for the management of agitation and delirium in 
the intensive care setting. Crit Care Med 2018;46:430. 
Reason for exclusion: Not original research. This is an abstract paper. Not a primary study. Author 
contacted. Paper yet to be published and was unavailable at the time of this review. 
 
Cruz JN, Tomasi CD, Alves SC, Macedo RC, Giombelli V, Cruz JG, Dal-Pizzol F, Ritter C. The incidence of 
delirium in patients pre-treated with statins who remain in an intensive care unit after cardiac surgery. Rev 
Bras Ter Intensiva. 2012;24(1):52-7. 
Reason for exclusion: Ineligible intervention. This was a prospective, observational, cohort prevention study. 
Not related to the treatment of post cardiac surgery delirium. 
 
Dale CR, Bryson CL, Fan VS, Maynard C, Yanez ND, Treggiari MM. A greater analgesia, sedation, delirium 
order set quality score is associated with a decreased duration of mechanical ventilation in cardiovascular 
surgery patients. Crit Care Med 2013;41(11):2610-7. 
Reason for exclusion: Ineligible intervention. Retrospective study on the quality order set and quality score 
for pain, sedation and delirium in the post cardiac surgery patient. Not related to delirium treatment.  
 
Das S, Forrest K, Howell S. General anesthesia in elderly patients with cardiovascular disorders: choice of 
anesthetic agent. Drugs Aging 2010;27(4):265-82. 
Reason for exclusion: Ineligible intervention. This is a practice guide on the effects of anesthetic on the 
elderly patient undergoing surgery. Not related to delirium treatment.  
 
Dattilio FM, Castaldo JE. Differentiating cognitive impairment from symptoms of anxiety in postcoronary 
artery bypass grafting encephalopathy: A case report. Neuropsychiatr Dis Treat 2006;2(1):111-6. 
Reason for exclusion: Ineligible intervention. This is a case report on anxiety and non-pharmacological 
treatment on the post-op coronary artery bypass graft patient. Not related to pharmacological treatment of 
delirium in the postop surgical patient. 
 
Davidson JE, Winkelman C, Gélinas C, Dermenchyan A. Pain, agitation, and delirium guidelines: nurses’ 
involvement in development and implementation. Crit Care Nurse 2015;35(3):17-31. 
Reason for exclusion: Not original research. This is a manuscript on the importance of nurse involvement in 
writing guidelines, example used pain, agitation and delirium. Not related to pharmacological treatment of 




DeForest A, Blinderman CD. Persistent delirium in chronic critical illness as a prodrome syndrome before 
death. J Palliat Med 2017;20(5):569-72. 
Reason for exclusion: Higher level study design located. This is a case presentation on caring for a patient 
with persistent delirium before death. Not a primary study. Not related to the pharmacological treatment of 
postop cardiac surgery delirium. 
 
Dianatkhah M, Ghaeli P, Talasaz AH, Karimi A, Salehiomran A, Bina P, Jalali A, Ghaffary S, Shahmansouri 
N, Vejdani S. Evaluating the potential effect of melatonin on the post- cardiac surgery sleep disorder. 
J Tehran Heart Cent 2015;10(3):122-8. 
Reason for exclusion: Ineligible intervention. This is an RCT, double-blinded on sleep improvement with use 
of melatonin commenced prior to CABG surgery. Not related to the pharmacological treatment of postop 
cardiac surgery delirium.   
 
Djaiani G, Silverton N, Fedorko L, Carroll J, Styra R, Rao V, Katznelson R. Reducing delirium after cardiac 
surgery: a multifaceted approach of perioperative care. [Internet]. NCT01378741. 2011[cited 2017 
December 12]. Available from 
https://clinicaltrials.gov/ct2/results?cond=Reducing+delirium+after+cardiac+surgery%3A+a+multifaceted+ap
proach+of+perioperative+care.+NCT01378741.  
Reason for exclusion: Ineligible intervention. This clinical trial is a prevention trial. Not related to the 
treatment of postop cardiac surgery delirium. Report paper written.  
 
Djaiani G, Silverton N, Fedorko L, Carroll J, Styra R, Rao V, Katznelson R. Dexmedetomidine versus 
Propofol Sedation Reduces Delirium after Cardiac Surgery: A Randomized Controlled Trial [Internet]. 
Anesthesiol 2016; 124(2):362-8. Available from: 
http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/961/CN-01168961/frame.html  
Reason for exclusion: Ineligible intervention. This is an RCT prevention trial. Not related to the treatment of 





Ellard L, Katznelson R, Wasowicz M, Ashworth A, Carroll J, Lindsay T, Djaiani G. Type of anaesthesia and 
postoperative delirium after vascular surgery. J Cardiothorac Vasc Anesth 2014;28(3):458-61. 
Reason for exclusion: Ineligible intervention. This is a retrospective study on the incidence of delirium in 
relation to the type of anesthetic that was used in vascular patients. Not related to treatment of delirium in 
the postop cardiac patient.  
 
Elkassabany N, Muravchick S, Fleisher LA. Thinking clearly about postoperative delirium and perioperative 
medications: how concerned should we be? Can J Anaesth 2009;56(11):785-8. 
Reason for exclusion: Not original research. This is an editorial. Not a primary study. Not related to 
treatment of delirium in the postop cardiac patient. 
 
Ellouze M, Badrudin D, Cartier R. Statins decrease incidence of delirium after OPCAB surgery. Can J 
Cardiol 2015;31(10):S173. 
Reason for exclusion: Not original research. This is a published abstract. Not a primary study. Not related to 
treatment of delirium in the postop cardiac patient. 
 
Erden O, Koner O, Temur S, Menda F, Bilgen S. Effects of ondansetron on sevoflurane induced pediatric 
emergence agitation. Br J Anaesth 2012;108:ii301. 
Reason for exclusion: Ineligible population. This is an RCT study re: use of ondansetron to prevent 
emergence delirium in the pediatric population.  
 
Esmat IM. Dexmedetomidine versus morphine and midazolam in prevention and treatment of delirium after 
adult cardiac surgery; a randomized, double-blind clinical trial. [Internet]. NCT03078946 2013 [cited 2017 
December 12]. Available from https://clinicaltrials.gov/ct2/show/NCT03078946 
Reason for exclusion: Ineligible intervention. This clinical trial is a prevention trial. At the time of searching 
no report was available. Report published 09 March 2018. Not related to the pharmacological treatment of 
postop cardiac surgery delirium with a focus of incidence of delirium. 
 
Evans A, Weiner M, Arora R, Chung I, Deshpande R, Varghese R, Augoustides J, Ramakrishna H. Current 
approach to diagnosis and treatment of delirium after cardiac surgery. Ann Card Anaesth 2016;19(2):328-
37. 
Reason for exclusion: Not original research. This is a review paper. Not a primary study. Not related to 
pharmacological intervention for the treatment of postop delirium.  
77 
 
Faught DD. Delirium: the nurse’s role in prevention, diagnosis, and treatment. Medsurg Nurs 
2014;23(5):301-5. 
Reason for exclusion: Not original research. This is an interest paper related to nurse education on raising 
awareness on delirium management and treatment. Not a primary study related to treatment of delirium in 
the postop cardiac patient.  
 
Firouzian A, Khezri HD. Can Glycyrrhiza glabra L. reduce delirium after coronary artery bypass graft 
surgery? Forsch Komplementmed 2014;21(6):418-9. 
Reason for exclusion: Not original research. This is a review paper on perioperative use of licorice for the 
prevention of delirium post CABG surgery. Not related to pharmacological intervention for the treatment of 
postop delirium.   
 
Flacker J, Marcantonio E. Delirium in the elderly: optimal management. Drugs Aging 1998;13(2):119-30. 
Reason for exclusion: Not original research. This is a management guideline. Not a primary study. Not 
related to pharmacological intervention for the treatment of postop delirium.  
 
Fok MC, Sepehry AA, Frisch L, Sztramko R, van der Burg BLS, Vochteloo AJH, Chan P. Do antipsychotics 
prevent postoperative delirium? A systematic review and meta-analysis. Int J Geriatr Psychiatry 
2015;30(4):333-44. 
Reason for exclusion: Not original research. Ineligible population. This is a systematic review re: drugs to 
prevent delirium in the postop patient. Excludes postop cardiac patients.  
 
Fong JJ, Devlin J. Can postoperative delirium be prevented pharmacologically? Crit Care Med 
2009;37(5):1825-6. 
Reason for exclusion: Not original research. Review paper. Not a primary study. Re: focus of prevention 
rather than treatment of delirium in the postop patient.   
 
Ford AH, Almeida OP. Pharmacological interventions for preventing delirium in the elderly. Maturitas 
2015;81(2):287-92. 
Reason for exclusion: Not original research. Ineligible population. This is a systematic review re: drugs to 




Ford AH, Flicker L, Passage J, Wibrow B, Anstey M, Edwards M, Almeida OP. The Healthy Heart-Mind trial: 
melatonin for prevention of delirium following cardiac surgery: study protocol for a randomized controlled 
trial. Trials 2016;17. 
Reason for exclusion: Ineligible intervention. This clinical trial is a prevention trial protocol. Not related to the 
pharmacological treatment of postop cardiac surgery delirium. 
 
Foushee J, Bush S, Furmanek D, Ohanuka E, Wright C, Kudlak J, Cass A. Postoperative delirium risk 
factors and outcomes in a cardiovascular intensive care unit. Crit Care Med 2010;38:A227. 
Reason for exclusion: Not original research. This is a published abstract. Unable to find full text. Author 
contacted but no response. Not a primary study. 
 
Fuentes Fernandez I, Moreno Flores A, Albacete Moreno C, Jara Rubio R. Basal cortisol relationship with 
the appearance of postoperative delirium. Eur J Neurol 2015;22:569. 
Reason for exclusion: Not original research. This is a poster presentation. Unable to find full text. Not a 
primary study. Not related to pharmacological intervention for the treatment of postop delirium. 
 
Fuhai., Li Z, Nguyen H, Young N, Shi P, Fleming N, Liu H. Perioperative dexmedetomidine improves 
outcomes of cardiac surgery. Circ 2013;127(15):1576-84. 
Reason for exclusion: Ineligible intervention. This is a retrospective cohort prevention study. Not related to 
the pharmacological treatment of postop cardiac surgery delirium. 
 
Fuhai, Li Z, Young N, Moore P, Liu H. Perioperative dexmedetomidine improves mortality in patients 
undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth 2014;28(2):267-73. 
Reason for exclusion: Ineligible intervention. This is a retrospective cohort prevention study. Not related to 
the pharmacological treatment of postop cardiac surgery delirium. 
 
Fukata S, Kawabata Y, Fujishiro K, Kitagawa Y, Kuroiwa K, Akiyama H, Takemura M, Ando M, Hattori H. 
Haloperidol prophylaxis for preventing aggravation of postoperative delirium in elderly patients: a 
randomized, open-label prospective trial. Surg Today. 2017;47(7):815-26. 
Reason for exclusion: Ineligible intervention. Ineligible population. This is RCT is a prevention trial. 
Population group is elderly abdominal and orthopedic surgical patients. Not postoperative cardiac surgical 




Gamberini M, Bolliger D, Buse GAL, Burkhart CS, Grapow M, Gagneux A, Filipovic M, Seeberger MD, 
Pargger H, Siegemund M, Carrel T, Seiler WO, Berres M, Strebel SP, Monsch AU, Steiner LA. Rivastigmine 
for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery-A 
randomized controlled trial. Crit Care Med 2009;37(5):1762-8. 
Reason for exclusion: Ineligible intervention. This RCT is a prevention trial. Not related to the 
pharmacological treatment of postop cardiac surgery delirium. 
 
Geng J, Qian J, Cheng H, Ji F, Liu H. The influence of perioperative dexmedetomidine on patients 
undergoing cardiac surgery: A meta-analysis. Plos One 2016;11(4). 
Reason for exclusion: Not original research. This is a meta-analysis. Not a primary study. Re: focus of 
prevention rather than treatment of delirium in the postop patient.  
 
Gosch M, Nicholas JA. Pharmacologic prevention of postoperative delirium. Z Gerontol Geriatr 
2014;47(2):105-9. 
Reason for exclusion: Not original research. This is a review paper on the prevention of postop cardiac 
surgery delirium. Not a primary study. Not related to the treatment of postop cardiac surgery delirium.  
 
Grey R, Brohan J. Dexmedetomidine use in ICU sedation and postoperative recovery in elderly patients and 
post-cardiac surgery [Internet]. NCT02699801. 2016 [cited 2017 December 12]. Available from 
https://clinicaltrials.gov/ct2/show/NCT02699801 
Reason for exclusion: Ineligible intervention. This clinical trial is a prevention trial. Currently in progress. No 
reporting of results available yet. Not related to the pharmacological treatment of postop cardiac surgery 
delirium. 
 
Giffhorn H. The incidence of delirium in patients pretreated with statins who remain in an intensive care unit 
after cardiac surgery. Rev Bras Ter Intensiva 2012;24(3):312-3. 
Reason for exclusion: Not original research. This is a letter to the editor. Not a primary study. Re: focus of 
prevention rather than treatment of delirium in the postop patient.  
 
Groen JA, Banayan D, Gupta S, Xu S, Bhalerao S. Treatment of delirium following cardiac surgery. J Card 
Surg 2012;27(5):589-93. 
Reason for exclusion: Not original research. This is a review paper. Not a primary study. Re: focus of 




Gu WE. Impact of dexmedetomidine sedation on the post-operative cognition dysfunction - a multiple 
center, randomized, controlled, double blinded clinical trial. [Internet]. NCT02275182. 2014 [cited 2017 
December 12]. Available from https://clinicaltrials.gov/ct2/show/NCT02275182 
Reason for exclusion: Ineligible intervention. This clinical trial is a prevention trial.  Results have not yet 
been published. Not related to the pharmacological treatment of postop cardiac surgery delirium. 
 
Hakim S, Othman A, Naoum D. Early treatment with risperidone for subsyndromal delirium after on-pump 
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(Group 1 n=26, 
Group 2 n=27) 
The intervention group received 
5mg morphine IM hourly until 
adequate sedation and a RASS 
score between -1 to +1 was 
achieved. Once the 20mg dose 
had been administered and the 
patient remained agitated then 
2.5mg lorazepam BD was 
administered per-oral was 
added to the treatment regime. 
The comparator group received 
5mg haloperidol IM hourly until 
adequate sedation and a RASS 
score between -1 to +1 was 
achieved. Once the 20mg dose 
had been administered and the 
patient remained agitated then 
2.5mg lorazepam BD was 
administered per-oral was 
added to the treatment regime. 
unknown 
It was determined that the 
patients who were 
receiving morphine 
treatment responded 
more quickly compared 
with the haloperidol 
treatment group. The 
overall results showed 
that 8 patients in Group 2 
(haloperidol group) 
received additional 
sedatives compared with 






(Group 1 n=40, 
Group 2 n-40) 
The intervention group was 
given 8mg of ondansetron IV 
and were evaluated before and 
10 mins after the injection with a 
4-point scale for the detection 
and evaluation of delirium. 
The comparator group was 
given 5mg of haloperidol IV and 
were evaluated before and 10 
mins after the injection with a 4-
point scale for the detection and 
evaluation of delirium.  
unknown 
Both ondansetron and 
haloperidol had excellent 
and equal delirium 









(Group 1 n=34, 
Group 2 n=38) 
The intervention group received 
a 0.3-0.7micrograms/kg/hr of 
dexmedetomidine IV. After the 
The comparator group received 
0.05-0.2mg/kg/hr of midazolam 
intravenously to control delirium. 
unknown 
Dexmedetomidine 
administration in this study 


















initiation of dexmedetomidine 
treatment, the background 
sedation of fentanyl and 
midazolam were weaned off and 
ceased. The dexmedetomidine 
dose was titrated on the basis of 
the patients’ heart rate and 
blood pressure response. 
Some patients in this group 
received haloperidol 5mg IM 4 
times per day for treatment of 
agitation as well as other drugs 
such as benzodiazepines, 
haloperidol or atypical 
antipsychotics. 
 
of delirium symptoms and 




Dexmedetomidine can be 
a good choice for the 
management of the 
delirium state associated 
with prolonged 
mechanical ventilation 
after cardiac surgery. 
Abbreviations: RASS – Richmond agitation sedation scale, BD – twice daily, IV – intravenous, IM – intramuscular, mg – milligram, mcg – microgram, kg – 
kilogram, hr – hour, mins - minutes 
 
 
 
